| 1-SA | Distinguishing Familial Chylomicronemia: Diagnostic Pitfalls And Clinical Implications | Nathan Kleinman | |
| 1-MSR | Using Abstract-Level Evidence Mapping to Prioritize Health Economic Modeling: Application to Tai Chi Systematic Reviews and Meta-Analyses | Björn Schwander | |
| 2-PCR | Patient-Reported Outcomes and Economic Burden by Atherosclerotic Cardiovascular Disease Risk in Japan: Analysis from the Japan National Health and Wellness Survey | Satoru Tanaka | |
| 2-MT | Cost Analysis of Continuous Glucose Monitoring (CGM) Policy Changes in Campania, Italy | Dagna Constenla | |
| 3-MSR | Impact of Time-to-Event Extrapolation on 36-Month Target Lesion Revascularisation Estimates for Covered Balloon-Expandable Stents in Aortoiliac Occlusive Disease | Kashfa Iqbal | |
| 4-RWD | Economic Burden of Chronic Kidney Disease in Chile Using Real World Data (RWD) From the Perspective of the Private Health System (ISAPRES) | Marina Tabares | |
| 4-HSD | Evaluating GLP-1 Receptor Agonist (RA) Utilization and Healthcare Resource Impact in Adults with Type 2 Diabetes, Pre-Diabetes, or Obesity Using Privacy-Preserving Synthetic EHR Data | Vicki Snavely | |
| 4-MT | Understanding Evidence and Reimbursement Pathways for Oncology Retreatment: A Cross-Country Assessment of Regulatory, Guideline, and HTA Perspectives | Marie Joelle Johnson | |
| 6-HSD | Trends in Prescribing of Hormone Replacement Therapy in Eligible Women Aged 40+ Using US Real-World Data: 2017-2025 | Janna Manjelievskaia | |
| 6-PCR | Mapping Patient Experiences with GLP-1 Receptor Agonists to the EQ-5D-5L Framework Using Online Community Forums | Omar Dabbous | |
| 6-EPH | Factors Associated with SGLT2 Inhibitor Initiation in Newly Diagnosed Type 2 Diabetes Patients: A Real-World Analysis from German Primary Care | Beate Leppert | |
| 6-MT | KWIT: A digital approach to support COPD screening and monitoring - Results from an innovative approach in France | Thibaut Goulvent | |
| 7-HSD | APPLICATIONS FOR ROMOSOZUMAB (EVENITY) UNDER A MANAGED ACCESS PROTOCOL IN IRELAND | Amelia Smith | |
| 7-MSR | Comparative Performance of the EQ-5D-5L and PROMIS-29 in Adults with Inflammatory Bowel Disease and Irritable Bowel Syndrome | Cassandra McLaughlin | |
| 8-CO | BRIDGE-T2D: A Real-World Framework and Prospective Study Design for Evaluating Impact of Dual Glycemic and Weight Control in Type 2 Diabetes | Jay Bae | |
| 8-HTA | Budget Impact Analysis of Souvenaid for the management of Alzheimer´s Disease in Middle East and North Africa region | Fardous Abozeid | |
| 8-EE | Cost-Consequence Analysis of Covered Balloon-Expandable Stents Using Extrapolated 3-Year Outcomes for Aortoiliac Occlusive Disease in the UK | Kashfa Iqbal | |
| 8-SA | Key Considerations for Synthesizing Cross-Country Oncology RWE Transportability Studies | Darren Johnson | |
| 8-RWD | Validating Self-reported Body Mass Index for Social Desirability Bias in a National Survey Linked with Electronic Health Records | Megan Jones | |
| 9-HPR | Role of Real-World Evidence in US FDA Safety Label Modifications - Insights from Case Studies | Anand Jacob | |
| 9-SA | A Systematic Literature Review (SLR) and Indirect Treatment Comparison (ITC) Feasibility Assessment in Homologous Recombination Repair (HRR)-Deficient Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | Neo SU | |
| 9-MT | The Budget Impact of Implementing an Outpatient Heart Failure Management System in the US | Alex Veloz | |
| 9-MSR | Modelling cure within health economic models: a framework to support health technology assessment bodies and manufacturers | Colleen Dumont | |
| 9-PCR | Health State Utilities Associated with Otoferlin-Related Hearing Loss | Timothy Howell | |
| 9-HSD | Current Treatment Patterns in Non-Metastatic Melanoma in the Modern Treatment Era: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis | Marianne Cunnington | |
| 9-PT | Evaluating AI versus Human-Led Inductive Thematic Analysis of Patient Interviews: A Case Study in Treatment Preferences for Non-Muscle-Invasive Bladder Cancer | Marie Hutchinson | |
| 9-RWD | Linking Pharmacy Claims and EHR-Derived Anthropometrics to Evaluate Real-World GLP-1 Outcomes in Obesity Leveraging NorstellaLinQ EHR and Vitals Data | Tori Rodgers | |
| 10-MT | Economic and Health Service Impact of Improved Healing in Hard-to-Heal Diabetic Foot Ulcers in the United Kingdom: A Cost-Consequence Analysis | Derek OBoyle | |
| 10-CO | Treatment Decision-Making in Inflammatory Bowel Diseases (IBD): A Canadian Survey Among Patients and Physicians in the CITE-IBD study | Chloe Langevin | |
| 10-RWD | Prescription Trends and Generic Market Share of Heparinoid Preparations in Japan from FY2014 to FY2024: A Longitudinal Claims Database Study | DIMITRA LAMBRELLI | |
| 10-HSD | TRUST-MM | Translating US Real-World Data to UK Clinical Practice: Treatment Patterns and Outcomes in First Line Relapsed/Refractory Multiple Myeloma | Andrew Thompson | |
| 11-CO | Comparison of the Psychometric Properties of the 3-Item and 23-Item versions of the Clinician Administered Dissociative States Scale (CADSS) | John Kealy | |
| 11-PT | Where Must the Human Remain in the Loop? Evaluating Expert-Validation Checkpoints in AI-Assisted HTA Evidence Workflows | Leah Moore | |
| 11-HPR | Most Favored Nation (MFN) in motion: new policy signals and global spillover effects | Craig Tallentire | |
| 11-EE | Cost-Utility of Early TAVI With the SAPIEN 3 Ultra RESILIA Valve Versus Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A French HTA | Pascal Candolfi | |
| 12-MSR | Variation in Conceptual and Operational Definitions of Depression in Real-World Research. | Katy Manni | |
| 12-HSD | Unlocking the Value of Biologic Therapies in Multiple Myeloma: The Potential of On-Body Injectors to Improve Healthcare Efficiency and Service Delivery | In Hon Henry Fong | |
| 12-RWD | Mental Health HEOR Evidence Generation and Growth of Real-World Evidence Amid Increasing Disease Burden: An AI-Assisted Longitudinal Analysis, 2014-2023 | Corrina Mau | |
| 12-PT | AI-Assisted Dental Caries Detection with Radiography: An Early Economic Evaluation in England | XIAOXIAN LIANG | |
| 13-EE | A Systematic Literature Review of the Economic and Humanistic Burden of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Brigitte Moore | |
| 13-EPH | Modelling Future Epidemiological and Economic Burden of HIV in Brazil: Projection of Substantial New Infections and Costs Through to 2034 | Thomas Bendall | |
| 13-PT | Content Validity Evaluation of Selected Patient Reported Outcome Measures for Pain, Fatigue, and Physical Functioning in Adults, Adolescents and Children Living with Osteogenesis Imperfecta | Elizabeth Gibbons | |
| 13-OP | Measuring Return on Investment in Real-World Data, Evidence, and Insights: Results from the 2025 Real-World Leaders Forum Benchmark Survey | Thomas Dougherty | |
| 14-HPR | Medical costs and healthcare resource utilization among Japanese epilepsy patients with and without frequent seizure-related emergencies: a comparative database study | Lorna Greenaway | |
| 14-HSD | Real World Use and Outcomes of Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer: A Retrospective Study from Italian Administrative Databases | Silvia Calabria | |
| 14-PCR | A Decision-Question Framework for Patient Preference Evidence in HTA and HEOR | Rachel Ryder | |
| 14-PT | Content Validation of the NTDT-PRO in Alpha-Thalassemia: A Hybrid Concept Elicitation and Cognitive Interview Study | Shweta Bapat | |
| 14-EE | Budget Impact of Introducing Accu-Chek® SmartGuide Real-Time Continuous Glucose Monitoring (rtCGM) solution for Diabetes Management in the UK NHS | Abbie Malyon | |
| 14-MSR | From Mechanism to Value: A Strategic Framework for Early Economic Modelling of Disease-Modifying Therapies Across the Development Lifecycle | Anand Jacob | |
| 14-RWD | Patient Characteristics, Treatment Patterns and Healthcare Resource Utilization in Neuromyelitis Optica Spectrum Disorder (NMOSD) patients in the Netherlands | Naomi Reimes | |
| 15-MT | Unlocking guideline adherence: the role of EMR-integrated identification tools in French COPD primary care | Thibaut Goulvent | |
| 15-PT | Exploring the Burden of Chronic Inducible Urticaria and the Meaningfulness of Treatment Using In-Trial Interviews | Caitlyn Matuska | |
| 15-HSD | Real-World First-Line Treatment (tx) Patterns in Androgen Receptor Pathway Inhibitor (ARPI)-Experienced Metastatic Castration-Resistant Prostate Cancer (mCRPC) by Race/Ethnicity and Area-Level Socioeconomic Status (SES) in the US | Valeria Merla | |
| 15-SA | Grey Areas: Does Grey Literature Belong in Every SLR? | Allie Cichewicz | |
| 16-MT | An AI Enabled Digital Twin for Simulating Anti-VEGF Treatment Strategies in Real-World nAMD Care | Ashwin Rai | |
| 16-CO | Contemporary Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Metastatic Uveal Melanoma in the United States | Aanan Misra | |
| 16-PCR | Creating a Shared Vision for Patient Partnered Research: an Example from the Producing an Arthritis Value Framework with Economic Evidence: Paving the way for Rare Childhood Disease (PAVE) project | Brittany Gerber | |
| 18-EPH | Epidemiology of Duchenne and Becker Muscular Dystrophy in Scandinavia:A Register-Based Analysis | Kelvin Kwok | |
| 18-HTA | Same Evidence, Different Prices? A Comparative Analysis of HTA Outcomes and Pricing Dynamics Across NICE and ICER | Marie Hutchinson | |
| 18-RWD | Five Clinically Distinct Chronic Lymphocytic Leukemia (CLL) Prescriber Personas Identified via Unsupervised Machine Learning Using NorstellaLinQ Real-World Data | Tori Rodgers | |
| 18-MSR | Automating Briefing Book Development for Major European Health Technology Assessment Submissions Using Generative AI | Saimithra Thammera | |
| 19-RWD | Evaluating the Robustness of Time-to-Event Analyses in De-Identified Real-World Dataset Using a Proxy Date of Death Algorithm: A Validation Study in Patients with Multiple Myeloma | Jiani Zhou | |
| 19-EPH | Evolving trends in pharmacotherapy for the management of attention deficit/hyperactivity disorder (ADHD) in Ireland | Amelia Smith | |
| 19-MT | Break-even Thresholds for Reducing Surgical Site Infection Following Caesarean Section: A Hospital-Based Economic Analysis in from a UK perspective | Derek OBoyle | |
| 20-EPH | Shifts in Treatment Patterns, Healthcare Resource Utilization, and Costs in NMOSD Following Introduction of Approved Therapies Post-2019 | Moushmi Singh | |
| 21-MT | A Total Cost of Ownership Model to Quantify the Value of RFID Integration in Pre-Filled Syringes | Matthias Borms | |
| 21-CO | Network Meta-Analysis (NMA) of Neoadjuvant-Adjuvant Treatment Pathways in HER2+ Early Breast Cancer (EBC) to Inform Cost-Effectiveness | Giorgia Rapesta | |
| 21-EPH | Understanding the Burden of Myelofibrosis: A Literature Review of Epidemiology and Natural History to Inform Value Assessment | Andrii Danyliv | |
| 21-PT | Differences in Patient Profiles Among Adults with Obesity Treated with GLP-1 Versus Non-GLP-1 Anti-Obesity Medications Using Real-World Data | Claire Campbell | |
| 21-RWD | A Generative AI Suite for Real-World Evidence Study Documentation: Multi-Module Validation Across Pharmacoepidemiological Deliverables | Massoud Toussi | |
| 21-SA | Adherence to the ISPOR Global Pharmacoeconomic Model Adaptation Guidance: A Review of Published Economic Model Adaptations | Eugenio Zucchelli | |
| 22-PT | Understanding How to Measure Whole Health: An Explorative Study to Identify Whole Health Tools for Outcomes Research | Tilly Stott | |
| 22-HTA | Developing Artificial Intelligence-Based Diagnostic Applications in Oncological Imaging: A Structured Expert Elicitation Study to estimate future value propositions | Jamie Verwey | |
| 23-RWD | Characterizing FGFR Biomarker Testing in Metastatic Urothelial Carcinoma Through NorstellaLinQ Linked Claims and Electronic Health Records, including Clinical Notes with Human-in-the-Loop LLM Extraction | Tori Rodgers | |
| 23-MSR | Navigating the PAIC Maze, Revisited: Methodological Updates and Regulatory Realities in NICE Submissions | Colleen Dumont | |
| 23-EPH | Estimating the UK Population Eligible for Late-line Multiple Myeloma Therapies Using an Epidemiological Model | Denise Zou | |
| 23-SA | Systematic Literature Review of Clinical and Economic Studies in Lipodystrophy Syndromes | Laura Cornic | |
| 24-CO | Oral Anticoagulation Program Reduces Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Ovarian Cancer: A Real-World Outcomes Study | Vicki Snavely | |
| 24-RWD | A Practical Framework for LLM-Assisted Abstraction and Validation of RWE Variables From Unstructured Physician Notes | Sarah Pytlak | |
| 24-EPH | Supporting Coverage Decision-Making Through a Collaborative Epidemiological Calculator: A Real-World Case Study in HR+ HER2- Metastatic Breast Cancer in Argentina | Marina Tabares | |
| 25-SA | Fit-for-Purpose Recruitment in Decentralized Observational Studies: Innovations, Use Cases, and Design Considerations | Elizabeth Donahue | |
| 26-HTA | A Structured Framework for Evidence Prioritization to Support Systematic Literature Review and Indirect Treatment Comparison in Joint Clinical Assessments: Application in ALK-Positive Non-Small Cell Lung Cancer | Jon Briggs | |
| 26-RWD | SOLAR: An observational study of the long-term effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis using data from the French Cystic Fibrosis Registry— Impact on quality of life and health utility values | Rashi Asthana | |
| 26-MSR | Reformulating PRO Estimators for Ordinal Outcomes in Oncology | Jamie Kettle | |
| 27-EE | Economic and Humanistic Burden of Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Systematic Literature Review | Atish De | |
| 27-MSR | Evaluating Complete Response (CR) and Progression-Free Survival (PFS) as Surrogate Endpoints for Overall Survival (OS) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) | Gabriela Mendoza | |
| 28-HTA | Benchmarking as a Tool for Assessing Cross-Country Comparability of Survival Evidence for HTA | Darren Johnson | |
| 29-MSR | Comparison of Naive versus Delayed-Entry Adjustment Methods in Real-World Survival Analysis of First-Line Metastatic NSCLC with PD-L1 TPS =50% | Ryan Thaliffdeen | |
| 29-SA | Indirect treatment comparison (ITC) of aumolertinib vs. osimertinib in advanced or metastatic EGFR mutated non-small cell lung cancer (NSCLC) in first-line and previously treated settings | kelly Makarounas-Kirchmann | |
| 29-RWD | Feasibility of Identifying Genotype-Defined Duchenne Muscular Dystrophy Populations Using Human-in-the-Loop LLM and Linked Clinical Notes from NorstellaLinQ EHR | Tori Rodgers | |
| 29-PCR | HEALTH STATE UTILITIES ASSOCIATED WITH TREATMENT FOR TRANSFUSION DEPENDENT ß-THALASSEMIA IN FRANCE | Rashi Asthana | |
| 29-EPH | Clinical Under-Recognition of Severe Hypertriglyceridemia Patients in Real World Practice: Insights from ICD Coding and Triglyceride Levels | Miriam Souto | |
| 29-MT | Short- and Mid-Term Outcomes of TEVAR in Descending Thoracic Aortic Pathologies: Insights From a French Nationwide Cohort | Lucie de Léotoing | |
| 30-SA | Comparison of Patient Characteristics and First-Line Treatment Patterns in Metastatic NSCLC: US and Finland Cohorts to Inform Overall Survival Transportability Analyses | Darren Johnson | |
| 31-PCR | Real-World EQ-5D-5L Utility Values in Adults with Transfusion-Dependent ß-Thalassemia Using UK and French Value Sets | Rashi Asthana | |
| 31-MT | NHS outsourcing cost implications of an AI-prioritised workflow for reporting Head CT in Emergency Care. | Athanasios Gkekas | |
| 31-RWD | Real-World Treatment Patterns, Adherence, and Healthcare Resource Use After Clinical Trial Participation in Women With Vasomotor Symptoms: Evidence From the OASIS STAR Linked Dataset | Lena Charafi | |
| 32-SA | Early Network Meta-Analysis in Generalized Myasthenia Gravis Using Time-Course Adjustment Through Model-Based Network Meta-Analysis | Saimithra Thammera | |
| 32-CO | Real-world clinical outcomes and correlation of recurrence free survival (RFS) and distant metastasis free survival (DMFS) to overall survival (OS) in resected stage IIB/C cutaneous melanoma | Yuexin Tang | |
| 32-MT | Clinical Roles of AI-Integrated Electroceuticals for Neurotransmitter Dysregulation Disorders: A Narrative Review | So Yoon Min | |
| 34-PCR | Combined Discrete Choice and Time Trade-Off methods to Estimate Utilities for the Sino-Nasal Outcome Test (SNOT-22) in Chronic Rhinosinusitis with Nasal Polyps | Elin Gruffydd | |
| 34-RWD | Long-term real-world patient-reported outcomes and urgency on adalimumab in ulcerative colitis: 36-month trajectories from the Ampersand digital cohort | Sreeram Ramagopalan | |
| 35-MSR | Why Advanced Psoriatic Arthritis Therapies Are Stopped and Switched, by Drug Class: Evidence From US Real-World Clinical Notes | Tori Rodgers | |
| 35-MT | Assessment of a Digital Medical Gas Management Platform: Insights from Healthcare Professionals on Workflow Efficiency, Safety, and Healthcare Resource Optimization in Italy | Alessandra Piemontese | |
| 36-MSR | Discrete Event Simulation of Chronic Kidney Disease in the USA | Miles Sondergaard Jensen | |
| 37-SA | Use and Acceptability of Structured Expert Elicitation in NICE Technology Appraisals | Ewa Rupniewska | |
| 37-RWD | Intercountry comparison of the Real World Data accessibility in Asia and Beyond: progress and challenges | Sabrina de Souza | |
| 38-MT | Cost-Utility Analysis of Closed Loop Stimulation Pacemakers versus Conventional Rate-Adaptive Pacing in the United Kingdom | Mikhail Kukushkin | |
| 38-MSR | mlumr: An R Package for Population-Adjusted Indirect Comparisons Using Multilevel Unanchored Meta-Regression | Ahmad Sofi-Mahmudi | |
| 38-RWD | A Global AI-Driven Code List Generation Tool with Integrated Japanese Medical Dictionary for Scalable Cross-Country Real-World Evidence | Luis Vaz | |
| 38-SA | AI-Assisted vs Manual Targeted Literature Reviews: A Case Study Evaluating Screening Efficiency and Data Extraction Accuracy | Saimah Raza | |
| 39-RWD | Representativeness of Broad-Consent Real-World Data: A Cross-Sectional Analysis of 3.5 Million Inpatients in the Helios Safe Medical Data Platform | Sabine Spaenig | |
| 39-HTA | Generative AI-Assisted Review of Cost-Effectiveness Evidence to Inform Health Technology Assessment Strategy | Ana Lozano | |
| 40-MSR | Retrospective Validation of a Source-Grounded AI-Enabled Evidence-Risk Triage Workflow for Anticipating Evidence Gaps in European HTA Appraisals | Leah Moore | |
| 40-SA | A Comparison of EHR and Claims-based Cohort Definitions on Real-World Research Results for Atherosclerotic Cardiovascular Disease (ASCVD) | Katy Manni | |
| 40-RWD | Long and Complex Femoropopliteal Segment Lesion Treatments in France: An Analysis of the French National Hospital Discharge Database | Lucie de Léotoing | |
| 41-CO | Leveraging Specialist Ophthalmology EMR Data to Evaluate Real-World Effectiveness of Anti-VEGF Therapies for Diabetic Macular Edema | Mark Yates | |
| 41-PCR | Development and Content Validity of the Hemophilia Universal Treatment Satisfaction Patient Reported Outcome (HUTS-PRO): A novel PRO for measuring treatment satisfaction across routes of administration. | Megan Smith | |
| 42-SA | Beyond MAIC: Leveraging ML-NMR for Parametric Survival Extrapolation in Indirect Treatment Comparisons | Trisha Whitney | |
| 42-MSR | Comparison of GPT-5 models for artificial intelligence (AI)-assisted data extraction from randomized clinical trials (RCTs) in systematic literature reviews (SLRs): accuracy, reproducibility, and time-efficiency | Sohan Deshpande | |
| 42-CO | Biomarkers Associated With Risk of Systemic Complications in Sjögren´s Disease: A Systematic Literature Review | Isabelle Lundqvist | |
| 42-EE | Economic Break-Even of Capacity-Reservation Models for Antiviral Pandemic Preparedness in Germany | Svenja Schwarz | |
| 43-HPR | Orphan Drugs, HTA Uncertainty and Access Inequalities: A Comparative Analysis Between France and Germany | Sarah Pytlak | |
| 43-MT | Assessing the Demographic Diversity of Participants Enrolled in Rare and Chronic Condition-Specific, App-Based Studies | Merika Sanders | |
| 44-HSD | A Data Driven Patient Pathway Analysis of The Clinical COPD Care in The Helios Hospitals in Germany | Dorian Fass | |
| 44-EE | Development of a New Cost-Effectiveness Model for Chronic Hepatitis B Virus Infection Based on the B-Well trial: Validation of Hybrid Cohort Model Approach | Catriona MacKinnon | |
| 44-CO | Public health impact (PHI) of recombinant zoster vaccine (RZV) for older adults and immunocompromised patients in Brazil | Costello Medical | |
| 44-HTA | Convergent but Not Equivalent: National HTA Evidentiary Flexibility and Residual Evidence Adaptation Under Joint Clinical Assessment | António Cardoso | |
| 44-MSR | Improving Efficiency in Real-World Evidence SLRs Without Compromising Validity: Implications for Biopharma | Anand Jacob | |
| 45-SA | Cost-Effectiveness of Continuous Glucose Monitoring in Type 2 Diabetes Mellitus: A Systematic Literature Review | Anne Ryschon | |
| 45-EPH | Public health impact and cost-effectiveness of increasing LAIV uptake in Estonian children | Maie Thetloff | |
| 46-RWD | Real-World Assessment of Liver Stiffness Measurement and Threshold Definitions in Primary Biliary Cholangitis: A Targeted Literature Review | Allie Cichewicz | |
| 46-PCR | Developing a Comprehensive Framework for Generating Patient Experience Data in Health Economics and Outcomes Research to Support Both Regulatory and HTA Requirements | Rachel Ryder | |
| 48-CO | A Systematic Literature Review of Studies Evaluating Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Brigitte Moore | |
| 48-SA | A Practical Framework for Including Dietary Data in Real-World Evidence Studies: Lessons From Inflammatory Bowel Disease and Pediatric Rare Diseases | Neil Brett | |
| 49-HTA | EU HTA in Practice: Member State Readiness and Early Lessons from the First JCA Reports | Dimitri Pouradier Duteil | |
| 49-RWD | Addressing Gaps in Real-World Mental Health Data: Feasibility of AI-Based Estimation of the PHQ-9 and CGI-I in Major Depressive Disorder | Ombretta Palucci | |
| 50-MSR | Practical Challenges in the Implementation of ML-NMR for Rate Outcomes: Lessons from a Recent European HTA Submission | Birgit Neu | |
| 50-SA | Investigating the Correlation Between Progression-Free Survival (PFS) and Overall Survival (OS) in first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). | Enrico de Nigris | |
| 51-HSD | Public preferences for a net-zero health care service | Caitlyn Matuska | |
| 51-PCR | FROM NARRATIVE TO NUMBERS: A MEDICAL ANTHROPOLOGY MODEL FOR TRANSLATING PATIENT-BASED EVIDENCE INTO HTA-READY METRICS | PAULA MARTONE MONTERO | |
| 52-RWD | Real-World Evidence External Control Arms in HTA Submissions of New Oncology and Rare Disease Therapies: Coverage Outcomes and Appraisal Timelines Across NICE, CDA-AMC, and PBAC (2020-2025) | Mackenzie Mills | |
| 52-EE | Informing Surgical Decision-Making through Evidence: A Randomized Trial-Based Cost-Utility Analysis of Periacetabular Osteotomy plus Arthroscopy for Hip Dysplasia | Lisa Masucci | |
| 53-EPH | Changes in the number of pregnancy and lactation post-marketing requirements/commitments issued by the FDA after the release of the draft Postapproval Pregnancy Safety Studies guidelines in 2019 | Yassaman Vafai | |
| 53-HSD | Bimekizumab Real-World Use in Psoriasis: Insights From a Multicenter, Multi-Year Retrospective Cohort Study in Spain, Results from the RUBIES Study | Costello Medical | |
| 53-PCR | Impact of Uncontrolled Hypertension on Patient Reported Quality of Life: Results from a Real-World Survey | Lucy Hargreaves | |
| 54-PCR | Health State Utilities Before and After Revascularization for Atherosclerotic Cardiovascular Disease: A Systematic Literature Review and Meta-Regression Analysis | Vishal Bali | |
| 54-RWD | Real-World Trends and Inter-Hospital Variation in First-Line Treatment and Time to Next Treatment in Metastatic NSCLC | Ana Merino-Vico | |
| 55-RWD | Unstructured Clinical Notes as a Source of Non-Small Cell Lung Cancer (NSCLC) Biomarker Information Beyond Structured Data: Evidence from NorstellaLinQ Real-World Data Unstructured Clinical Notes as a Source of Non-Small Cell Lung Cancer (NSCLC) Biomarker | Tori Rodgers | |
| 55-HSD | Mortality, Disease Burden and Healthcare Resource Use in Patients with Transthyretin Amyloidosis with Cardiac Involvement in Spain: Results from the OverTTuRe Global Study. | Joaquín Sánchez-Covisa | |
| 55-HPR | An Actuarial Approach to Managed Access Agreements: Addressing Surrogate Endpoints, Data Silos, and Legal Procurement Constraints in Resistant Hypertension | Lazaro Poey | |
| 55-PCR | Health utility values measured by EQ-5D in patients with post-stroke hemiplgia: a systematic review and meta-analysis | SOOBIN JANG | |
| 56-EE | Updated Cost-Effectiveness of Lecanemab in Early Alzheimer´s Disease: A Canadian Societal Perspective | Trisha Whitney | |
| 56-HSD | Evaluation of the impact of a recommended shift in glycaemic management targets for older adults on clinical outcomes and healthcare expenditures in Japan: An interrupted time-series analysis using a nationwide health insurance claims database | Naoki Takashi | |
| 56-CO | Depression Severity Change Following Initiation of GLP-1 Versus Non-GLP-1 Anti-Obesity Medications Using Real World Data | Claire Campbell | |
| 58-MSR | Aligning Target Product Profiles with HTA Requirements Through AI-Assisted Living Systematic Literature Reviews: A Conceptual Framework | Colleen Dumont | |
| 58-RWD | Real-World Utilization of Talazoparib Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer in the United States | Neo Su | |
| 58-EE | Economic Impact Of Embolic Agent Choice (Liquid Vs Particles) In Middle Meningeal Artery Embolization For Chronic Subdural Hematoma : A National Healthcare System Perspective | FRANCESCA MARIANI | |
| 59-RWD | Gaining Efficiency in the integration of a Multimodal Oncology Real-World Data source into an Enterprise Analytics Platform | Sabrina de Souza | |
| 59-HPR | Reducing Frailty in Older Adults in the UK: Estimated Cost Savings and Quality-of-Life Benefits | Stacey Chang-Douglass | |
| 59-EE | Costs by Disability Severity and Association with EDSS in Multiple Sclerosis across EU5: A Targeted Literature Review | Pragya Sinha | |
| 60-RWD | Treatment Patterns Among FGFR-Positive Metastatic Urothelial Carcinoma Patients: A NorstellaLinQ Claims and EHR Analysis | Tori Rodgers | |
| 60-PCR | Reconstructing Adaptive GLP-1 Receptor Agonist Patient Journeys from Online Community Narratives | Omar Dabbous | |
| 60-SA | Optimizing the Integration of AI in a Complex Systematic Literature Review: Validation Across Title/Abstract and Full-Text Stages | Niamh McGuinness | |
| 61-RWD | Migration Between Academic And Community Treatment Settings From Diagnosis To Treatment Among Patients With Breast Cancer: A Real-World Analysis Leveraging NorstellaLinQ EHR And Claims | Tori Rodgers | |
| 61-PCR | Adult Phenylketonuria Multidimensional Burden of Illness: A Qualitative Study | Zoe Wagg | |
| 62-CO | From Hazard Ratio to Clinical Impact: Number Needed to Treat in Platinum-Resistant Ovarian Cancer | Auston Collins | |
| 62-HPR | Do HTA agencies stick to their ICER thresholds? Cross-jurisdictional evidence from Australia, Canada, and England (2020-2025) | Mackenzie Mills | |
| 62-SA | Adapting Global Patient-Centered Research Methods to Japan: a Practical Framework for Regulatory, Ethical, and Site-Level Implementation | DIMITRA LAMBRELLI | |
| 63-EE | Budget impact of post-stroke spasticity management using abobotulinumtoxinA: Hospital-at-Home versus Traditional Hospital Care - a French perspective | sandra boiziau | |
| 63-HSD | Black-White Differences In Surgical Receipt In Male Breast Cancer Patients | Catherine Cooke | |
| 63-EPH | Frailty Severity as a Marker of Healthcare Need Across Outpatient, Acute-Care and Home-Care Settings - A Population-Based Cohort Study of Older Adults | Galia Zacay | |
| 63-CO | Efficacy and Safety of First-Line Treatment Strategies in RAS/KRAS-Mutated Metastatic Colorectal Cancer: A Systematic Literature Review | Bjoern Stollenwerk | |
| 64-SA | Adapting Rapid Review Methods for HEOR Decision-Making: A Fit-for-Purpose Framework for Efficient Evidence Synthesis | Kassandra Schaible | |
| 64-MSR | Developing and Evaluating an AI-Assisted Agentic Pipeline for Excel-to-R Migration of Health Economic Models | Varyam Memon | |
| 65-SA | Information-Thresholded Network Meta-Analysis: Feasibility and Impact in a Mature Evidence Network | Teuta Gjuladin-Hellon | |
| 65-HTA | Inside CEESP technical exchanges: methodological signals from recent French economic assessments | Sarah Pytlak | |
| 66-CO | Treatment Duration and Clinical Outcomes with Tumor Treating Fields in Swiss Patients with Glioblastoma: A Real-World Analysis | Jorge Fernando Nino de Rivera | |
| 66-HSD | From Ambiguity to Agreement: Strengthening eDelphi Consensus Through Rigorous Survey Instrument Design | Megan Jones | |
| 67-EPH | Epidemiology and Outcomes of Chronic Hepatitis B in Brazilian Adults: A Nationwide Analysis, 2010-2025 | Jacqui Tan | |
| 67-CO | Unlocking Chronic Lymphocytic Leukemia (CLL) Disease Stage in Real-World Data: Clinical Notes as the Primary Source of Rai and Binet Staging Information Using NorstellaLinQ | Tori Rodgers | |
| 67-RWD | Real-World Treatment Patterns, Healthcare Resource Utilization, and Unmet Needs in Generalized Myasthenia Gravis: A Retrospective Analysis of German Statutory Health Insurance Claims | Wisam Karmous | |
| 68-PCR | Identifying Fit-for-Purpose Observer Reported Outcomes by Cross Comparing Regulatory Perspectives and Validity Evidence in Interconnected Databases | Tilly Stott | |
| 68-HSD | Real-World Corticosteroid Burden Reduction with Subcutaneous Immunoglobulin IgPro20 in CIDP | Antoaneta Rashkova | |
| 68-SA | Systematic literature review and critical appraisal of cost-effectiveness models of antimicrobial treatments | James Dennis | |
| 69-CO | From Implementation to Inference: How eCOA Execution Shapes PRO Data Interpretability | Lindsay Hughes | |
| 69-PCR | Beyond Reference Guides: Embedding Behavioral Science in eCOA Training Strategy | Lindsay Hughes | |
| 70-RWD | Real-World Healthcare Resource Utilization and Treatment Patterns Among Patients With Hidradenitis Suppurativa in Canada Using AI-Extracted Data | Ruth Moulson | |
| 71-SA | Validation of Data Extraction by an Agentic AI Literature Review Platform Against Manual Review | Niamh McGuinness | |
| 71-RWD | Long-term reduction in patient-reported blood-in-stool entries on adalimumab in ulcerative colitis: real-world evidence from the Ampersand digital cohort | Sreeram Ramagopalan | |
| 72-HTA | Beyond the ICER: Assessing the Uptake of Broader Value Outcomes in French HTA Appraisals | Colleen Dumont | |
| 72-RWD | Real-world Healthcare Costs and Resource Utilization Associated with Paclitaxel-Coated Balloon vs. Urethroplasty for Urethral Stricture: A US Claims Analysis | JAYANT KUMAR SUPPAL | |
| 73-MSR | Comparing the Performance of Estimators for Transporting Trial Treatment Effects to Target Populations Under Varying Positivity: A Simulation Study | Ting-An Tai | |
| 73-SA | Current Treatment Patterns and Safety Outcomes in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With an NPM1 Mutation: A Systematic Literature Review (SLR) | Anne Brown | |
| 74-PCR | An 8-Point Worsening And A 10-Point Improvement On The Multiple-Sclerosis Impact Scale 29-Item (MSIS-29) V2 Are Clinically Meaningful | Ying-Fang Chen | |
| 74-CO | Informing Early Clinical Programs With External Control Arms and Target Trial Emulation | Samantha Wilkinson | |
| 74-RWD | Association between orthopaedic robotic surgical systems and staff sickness absence in NHS hospitals: a multi-centre FOI analysis with workload-based interpretation | Catherine Whittall | |
| 75-HSD | Physicians´ Perceptions and Barriers to Code Status Discussions in Saudi Arabia: A Sequential Mixed-Methods Study | Rim Itani | |
| 75-MSR | Goldilocks and the Three Retrieval Approaches: Human-Reviewed Validation of Large Language Model (LLM) Embedding-Driven Retrieval for Trustworthy Evidence Gap Analysis and Value Dossier Drafting | Tyler Reinsch | |
| 75-RWD | Improving Identification of Patients, Caregivers, and Healthcare Professionals in Social Media Data Using Fine-Tuned Pretrained Language Models in French and English | Stéphane Schück | |
| 76-HSD | Prolonged Emergency Department Length of Stay and Alternate Level of Care Status as Markers of Prolonged Hospitalization Among Older Adults: An Exploratory Synthetic Data Analysis | Vicki Snavely | |
| 76-PCR | Effect of Multi-Cancer Early Detection (MCED) Testing on Participant-Reported Outcomes for Mental Health-Related Quality of Life (MHRQoL) in PATHFINDER 2 | Heather Hamadyk | |
| 78-RWD | Prescriber Intent Versus Treatment Initiation for Biologic Therapies in Atopic Dermatitis: A Real-World Analysis Using NorstellaLinQ US Linked e-Prescription, Claims, and Payer Data | Tori Rodgers | |
| 78-HSD | Real-World Drivers of Clinical Decision-Making in Atrial Fibrillation: Understanding Subjective Reasons for Non-Initiation of Oral Anticoagulants | Sandra Cusco | |
| 79-SA | Evaluating the Feasibility of Indirect Treatment Comparisons in Patients with epNEC Treated in Second-Line and Beyond (2L+): A Guideline-Informed Systematic Literature Review and Feasibility Assessment | Karolin Eberle | |
| 79-MSR | Transporting Real-World Outcomes of Patients from the United States to the United Kingdom: the Challenging Use Case of Patients with Schizophrenia | Florence Brellier | |
| 80-RWD | A 10 Year Retrospective Review of Dose Modification of Infliximab Therapy in Private Hospitals in Ireland | Patrick Malone | |
| 80-EE | Evaluating the Economic Impact of Earlier CAR T Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: a 24-Month Cost Sequencing Analysis from the Brazilian Private Healthcare Perspective | Jessika Cristina Bridi | |
| 80-CO | Revised Assessment of Attack-Free Outcomes in Hereditary Angioedema: An Updated Network Meta-Analysis of Prophylactic Treatments | OPEN Health | |
| 81-RWD | Financial and Access Barriers from Clinical Notes Using Human-in-the-Loop LLM: Evidence from a PCSK9 Inhibitor-Treated Cohort Using NorstellaLinQ | Tori Rodgers | |
| 81-MSR | Fit For Purpose? Purpose Built Artificial Intelligence (AI) Tools vs General Purpose Large-language Model (LLM) for Data Extraction in Evidence Synthesis | Allie Cichewicz | |
| 82-SA | Delphi and Expert Consensus Across the Product Lifecycle: A Framework to Enhance Real-World Evidence (RWE) Planning in Health Economics and Outcomes Research (HEOR) and Health Technology Assessment (HTA) | Fiona Glen | |
| 82-HSD | Environmental impact assessment for total knee replacement care pathway and subsequent prosthetic joint infection | Tom Binstead | |
| 82-PCR | Impact of Treatment Status on EQ-5D-5L Utilities in Alpha-Mannosidosis: A Vignette Study | Tracy Odigie | |
| 83-PCR | Systematic Literature Review of Treatment Preference Elicitation Studies in Sickle Cell Disease | George Morgan | |
| 84-PCR | Comparative EQ-5D-5L Utility Outcomes Across Pegunigalsidase Alfa Regimens and Agalsidase Beta in Adults With Fabry Disease | Khashayar Azimpour | |
| 84-HPR | Aligning Evidence Generation with Evolving Market Access Pathways and Regulatory, HTA, Payer, and Implementation Needs: A UK Example | Rachel Ryder | |
| 84-RWD | Discordance Between ICD-10-CM Obesity Diagnosis Codes and Exact BMI Measurements in Electronic Medical Records: A NorstellaLinQ EHR and Claims Validation Study | Spencer Friedman | |
| 84-EE | Optimizing Cancer Care Delivery in Argentina: Institutional Budget and Capacity Impact of Subcutaneous Pembrolizumab | Lucas Perelli | |
| 84-MSR | Development and Validation of a Disease Model for Non-Small Cell Lung Cancer | David Griffin | |
| 85-MSR | When Guidance Meets Reality: Lessons From Recent HTA Submissions in Reporting Effect Modifiers | Colleen Dumont | |
| 85-PCR | A Real-World, Global Survey of the Burden of Hemophilia A and B on Patients with Inhibitors. | Maria Gheorghe | |
| 85-RWD | Description and Burden of Portal Hypertension Treatments in France: A National Hospital Database Analysis | Lucie de Léotoing | |
| 85-EPH | Burden of HPV-related cancers in Europe: incidence across 27 countries | Ugne Sabale | |
| 86-SA | Living Literature Reviews: Maintaining Quality in Real-Time Evidence Synthesis | Rachel Ryder | |
| 87-HSD | Real-World Treatment Patterns in Chronic Lymphocytic Leukemia: A Systematic Review | Katherine Gibbs | |
| 87-PCR | Estimating Utilities for Health States Associated with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Using EQ-5D-5L and Time Trade-Off Methodologies | Elin Gruffydd | |
| 87-RWD | A Large Population with Clinically Meaningful Evidence of Alcohol Use Disorder (AUD) Is Not Captured by Diagnosis Codes Alone: Evidence from NorstellaLinQ Structured and Human-in-the-Loop Large Language Model (LLM) Extracted Clinical Data | Tori Rodgers | |
| 87-EPH | Characteristics and Treatment Patterns of Patients with Spinal Muscular Atrophy in the United States | Crystal Watson | |
| 88-SA | Impact on Healthcare Resource Utilization, Costs, and Greenhouse Gas Emissions following Sodium Zirconium Cyclosilicate Initiation in Patients with Hyperkalaemia in Spain: The VITALIZE Study | Joaquín Sánchez - Covisa | |
| 88-HSD | From Data to Clinical Transformation: Self-Service Analytics as a Catalyst for Nursing-Led Reduction in Chemotherapy Treatment Wait Times | Vicki Snavely | |
| 88-CO | Development of a UK HES-Based Framework to Quantify Organisational Burden in Complex Thoracic Aortic Repair | Mitesh Nakum | |
| 88-RWD | Clinical and Economical Burden of Chronic Sedative-Hypnotic Use for Insomnia Disorder: A Nationwide French Claims Database Study | Sarah Pytlak | |
| 89-HPR | Managed Entry Agreements (MEAs) in Greece: Stakeholder Perspectives on Outcome-Based Reimbursement and Healthcare System Readiness | IOANNIS GASIAS | |
| 89-PCR | Real-World Behavioral Clustering Reveals Three Actionable patients with COPD throughout Archetypes for Tailored Interventions | Thibaut Goulvent | |
| 89-HSD | Exploring the Future Treatment Landscape of Relapsed/Refractory Multiple Myeloma (RRMM): How Clinical Trial Line of Therapy (LoT) Eligibility May Reshape Treatment Sequencing | Steven Banks | |
| 90-RWD | Extracting Patient-Centric Disease Progression Insights From NorstellaLinQ Clinical Notes: MG-ADL Scores in Myasthenia Gravis Using Unstructured Real-World Data | Tori Rodgers | |
| 90-HPR | National Implementation of the EU HTA Regulation: Progress and Approaches Across European Countries | George Wang | |
| 90-MSR | BENEFIT AND BURDEN OF MULTI-CANCER DETECTION - A BAYESIAN, SIMULATION-BASED ANALYSIS | Reinier Meester | |
| 90-SA | Published Clinical and Economic Evidence as a Prerequisite for Assessing the Value of Continuous Glucose Monitoring Systems (CGM) | Ula Ona Kibildyte | |
| 91-RWD | Geographic Variation in How Physicians Conceptualise, Assess and Act on Disease Activity and Progression in Multiple Sclerosis: A Real-World Multi-Country Survey | Tom Chambers | |
| 91-SA | A Pragmatic Cluster-Randomized Real-World Study of Biologic Therapy in Inflammatory Bowel Disease in a US Community Gastroenterology Network | Nicholas Lazarou | |
| 92-CO | The incidence of kidney failure and the impact of proteinuria in people with IgA nephropathy: A systematic review and meta-analysis | Antonio Ramirez de Arellano | |
| 93-HPR | Assessing the Potential Impact of U.S. Most-Favored-Nation Pricing Models on Innovative Drug Launches in Czechia | ARIEL HAMMERMAN | |
| 93-HSD | Exploring barriers to shared decision-making (SDM) in rare diseases from the physician perspective in Europe: findings from a cross-sectional survey | Megan Jones | |
| 93-EE | Real-World Costs and Healthcare Resource Utilization for Patients With Metastatic Non‒Small Cell Lung Cancer and PD-L1 TPS ≥50% in the United States | Natalie Polsky | |
| 93-CO | Relative Vaccine Effectiveness of the Co-Administration of Influenza and COVID-19 Vaccines Compared to Influenza Alone, Among Children in the US in Fall 2023-2024 | Janna Manjelievskaia | |
| 93-PCR | Targeted Literature Review of the Benefits and Limitations of Current Moderate-to-Severe Psoriasis (PsO) Routes of Administration | Trisha Whitney | |
| 93-EPH | Assessing the Environmental Burden of Chronic Obstructive Pulmonary Disease in Spain and Opportunities for Emission Reduction | Joaquín Sánchez-Covisa | |
| 93-RWD | DEVELOPMENT OF AN INTEGRATED FRAMEWORK AND AI-ASSISTED PLATFORM FOR COMPLIANT AND SCALABLE REAL-WORLD EVIDENCE GENERATION USING REGIONAL HEALTHCARE DATA IN CHINA | DIMITRA LAMBRELLI | |
| 94-MSR | Improving Identification of Patients Eligible for Endogenous Cushing Disease Treatment Through Clinical Expertise and Machine Learning | Andrea Seltmann | |
| 94-PCR | Spotlight on Sjögren´s: Disease Burden and Unmet Needs for patients in the United Kingdom (UK) | Thomas Dewar | |
| 94-SA | Real-World Study of Uptake of Enfortumab Vedotin (EV) in First-Line (1L) Treatment of Locally Advanced/Metastatic Urothelial Cancer (la/mUC) in the US | Gillian Anderson | |
| 95-HTA | How Is Real World Evidence Used in Prostate Cancer HTA?Insights from NICE Appraisals 2016-2026 | Charlotte Johnston | |
| 95-RWD | From Broad Lung Cancer ICD-10 Codes to Confirmed Non-Small Cell Lung Cancer (NSCLC): Human-in-the-Loop Large Language Model (LLM) Extracted Clinical Notes Enable Histology and Stage Stratification Not Achievable from Structured Data Alone Using NorstellaL | Tori Rodgers | |
| 95-MSR | Performance of an AI-Powered Digital Phenotyping Platform for Patient Identification in Three Conditions With Systematic Undercounting in Real-World Data | Ombretta Palucci | |
| 95-HSD | Emergency Department Triage Acuity Among Influenza-Related Visits in the United States | Anita Mohandas | |
| 96-HPR | Potential Patient Opportunity Loss Associated with Delayed and Absent Access to Newly Approved Medicines in France: A Cross-Country Analysis | Sarah Pytlak | |
| 98-PCR | Who is a caregiver? A targeted review of eligibility criteria in qualitative research with caregivers | Catherine Bottomley | |
| 98-SA | The CAPTURED Trial: Can algorithms and quality Improvement support for primary care lead to earlier diagnosis for specific rare disease patients? | David Price | |
| 98-HTA | Can AI-Assisted SLRs Meet HTA Standards? Evidence From a NICE Single Technology Appraisal | Hannah Harrington | |
| 99-HTA | A Review of SACT Data Used in NICE Technology Appraisals | James Gould | |
| 99-HPR | Assessment of Medicines in Catalonia (Spain) in 2025: Economic Evidence and Gaps | Diana Nieves | |
| 99-SA | FROM STRUCTURAL TO PARAMETER UNCERTAINTY: EVIDENCE OF REFERENCE MODEL MATURITY IN DUCHENNE MUSCULAR DYSTROPHY HEALTH TECHNOLOGY ASSESSMENTS | Sarah Pytlak | |
| 100-EPH | Understanding Patients´ Knowledge, Attitudes and Perceptions to Herpes Zoster Infection and Vaccination in Germany: Results from a Cross-Sectional Survey | Hannah Russell | |
| 100-SA | A Generalized Modelling Framework for the Indirect Estimation of Hospitalizations Attributable to Specific Respiratory Viruses Incorporating Multi-pathogen Dynamics and Pandemic-disrupted Study Periods | Robin Bruyndonckx | |
| 100-HSD | A Budget-Neutral Utilization-Credit Incentive to Improve Operating Room Capacity Management: A Pre-Post Study | Melana Elliot | |
| 101-HTA | A Structured Multi-Criteria Decision Framework for Global Launch Prioritization of Innovative Oncology Medicines: A Conceptual Methodology | Kalman Wijaya | |
| 101-MSR | Automated Quality Control of Health Economic Excel Models Using a Large Language Model Agent: A Multi-Model Validation Study | Andre Verhoek | |
| 101-RWD | Diagnosis-Based Healthcare Organization Attribution Frequently Misclassifies Treating Organizations in Breast Cancer: A Real-World Analysis Using NorstellaLinQ EHR and Claims | Tori Rodgers | |
| 101-EPH | COST-EFFECTIVENESS ANALYSIS OF EXPANDED INFLUENZA VACCINATION COVERAGE WITH LIVE ATTENUATED INFLUENZA VACCINE (LAIV) IN CHILDREN AGED 2-11 YEARS IN CATALONIA (SPAIN) | Guillermo Sanchez | |
| 102-RWD | Improving Real-World Identification and Molecular Characterization of Diffuse Midline Glioma Using Human-in-the-Loop LLM Extraction of NorstellaLinQ Unstructured Electronic Health Record Clinical Notes | Tori Rodgers | |
| 102-EE | Characterizing Weight Distribution Patterns in Individuals with Achondroplasia Across Age: Evidence from the CLARITY Cohort with Implications for Economic Modeling | Laura Cahill | |
| 103-HTA | Preparing for Joint Clinical Assessment: Comparing HTA Comparators, Clinical Practice, and Real-World First-line NSCLC Treatment in the EU4 + UK | Gabriela Mendoza | |
| 103-PCR | Exploring narrative accounts as a distinct qualitative data collection method | Millie Gaydon | |
| 103-EE | Budget Impact of Subcutaneous Immunoglobulin 20% (IgPro20) in CIDP from a German Statutory Health Insurance Perspective | Antoaneta Rashkova | |
| 104-CO | VENTURE-1: Impact of VK2735, a Dual Incretin Agonist, on Predicted Cardiovascular Disease Risk | Karen Chung | |
| 104-HTA | Beyond PICO Prediction: A Systematic Framework for Evidence Gap Analysis and Strategic Prioritization for European Union Joint Clinical Assessment (EU JCA) Readiness | Valery Risson | |
| 105-MSR | Computer-Aided and Computer-Generated Content as Reasons for Retraction in Meta-Analyses: A Temporal Analysis of the Retraction Watch Database | Daniel Shaw | |
| 106-SA | A summary of guidance and methods for identification of prognostic factors in a systematic review for a JCA dossier evidence synthesis workflow | Jon Briggs | |
| 106-RWD | Equity by Design: A Nationwide Geospatial Assessment of Brazil´s Capacity to Deliver Intravenous ALS Therapies | Sarah Rodrigues | |
| 106-PCR | Food Insecurity and Antihypertensive Medication Adherence Among Adults with Hypertension: A Real-World Study | Claire Campbell | |
| 106-EE | Economic Impact of Oral Corticosteroid-Related Comorbidities in Patients With Acetylcholine Receptor Antibody-Positive (AChR-Ab+) Generalised Myasthenia Gravis (gMG) in the United States (US) | Michaela Osborn | |
| 107-RWD | Preferences of People Living with HIV for Injectable versus Oral Antiretroviral Therapy (ART): A Discrete Choice Experiment (DCE) across China, US, UK, Spain, and Germany | Anna George | |
| 109-RWD | Development And Validation Of A Prediction Model To Estimate The Hurley Score In Patients With Hidradenitis Suppurativa | Ombretta Palucci | |
| 109-CO | Artificial Intelligence For Data Extraction In Live HEOR Literature Reviews: A Real-World Analysis Across More Than 20 Reviews | Anand Jacob | |
| 109-HTA | Qualitative Content Analysis of Responses to the NICE Public Consultation on Exa-cel for the Treatment of Patients with Severe Sickle Cell Disease | Rashi Asthana | |
| 110-HTA | Assessing Orphan Medicines under the European Union (EU) Health Technology Assessment Regulation (HTAR): Is Current HTA Guidance Fit for Purpose? | Andreas Freitag | |
| 110-EPH | Primary non-adherence and associated factors in patients with atrial fibrillation in Germany - a retrospective cohort stud | Beate Leppert | |
| 110-EE | Burden of illness of Metachromatic leukodystrophy - An AI assisted targeted literature review | Rishabh Verma | |
| 110-RWD | Wearable Physiological Signals as Correlates of Patient-Reported Disease Control in IBD: A Real-World Exploratory Analysis from the Ampersand Digital Cohort | Sreeram Ramagopalan | |
| 111-MSR | A Standardized Methodological Framework for AI-Assisted Extraction of Real-World Clinical Data from Hospital Information Systems | Isabelle DELAROZIÈRE | |
| 112-EPH | Healthcare Resource Utilization and Outcomes in Pulmonary Arterial Hypertension: Evidence from a Tertiary Center in Argentina | Lucas Perelli | |
| 112-HSD | An analysis of IV-to-Subcutaneous Oncology Drug Transitions Framed by Implementation Science: Why Clinical Efficacy Alone Fails to Drive Adoption | Rachel Ryder | |
| 113-EE | Clinical and economic impact of switching patients with severe eosinophilic asthma controlled on benralizumab to depemokimab in the United States | Andre Verhoek | |
| 113-RWD | Accelerating real-world evidence studies through AI-Assisted evidence integration | Sarah Pytlak | |
| 113-MSR | Where NOT to Use AI in Health Economic Modeling: An Agentic Platform with Clear Trust Boundaries | Liza Zasukhina | |
| 113-HPR | Biosimilar-Enabled Access and Repositioning (BEAR): A Framework for Lifecycle Assessment and Repositioning of Biologic Therapies Informed by Cross-Country Evidence and Stakeholder Recommendations | Natasha Jackson | |
| 113-PCR | Evolution of Social Media Conversations About Obesity and GLP-1 Treatments in France Between 2016 and 2026 : A Social Listening Study | Nathalie Texier | |
| 114-PCR | Early Adoption of the ICHOM Set for Obesity and Development of a Federated Data-Sharing Network to Support International Outcomes Benchmarking | Zofia Das-Gupta | |
| 114-MSR | AI-Assisted RWE Study Design and Reporting: Quantifying Time Savings and Scientific Equivalence Across Protocol, SAP, Code, and Report and Manuscript Generation | Massoud Toussi | |
| 114-HTA | Early Evidence PICO Multiplicity Under the EU HTAR: Insights from the Inaugural Joint Clinical Assessment | Leah Moore | |
| 114-EPH | Identifying Obesity in Administrative Health Data: Trends and Overlap of Diagnosis Codes, Bariatric Procedures, and Anti-Obesity Medications in Alberta, Canada | Tara Cowling | |
| 115-CO | Prognostic Impact of RAS/KRAS Mutation Status on Survival Outcomes in First-Line Metastatic Colorectal Cancer: A Systematic Literature Review | Bjoern Stollenwerk | |
| 116-RWD | Bridging Real-World Data Across Borders: A Comparative Mapping of Health Data Resources in Alberta, Canada and England | Tara Cowling | |
| 116-EPH | Estimating the Global Prevalence of Turner Syndrome: A Systematic Literature Review and Meta-Analysis | Laura Cahill | |
| 117-RWD | Predicting Future Cardiovascular Adverse Events at Population Scale Using a Real-World Dara Foundation Model: Implications for Clinical Trial and Launch Planning | Ombretta Palucci | |
| 118-CO | Assessing the Public Health Impact of Belantamab Mafodotin, Bortezomib, and Dexamethasone in relapsed or refractory multiple myeloma: QALY Results from a Brazilian Perspective | Costello Medical | |
| 118-MSR | Global Trends And Disparities In The Use Of Clinical Outcome Assessments In ClinicalTrials.gov, 2015-2025: An AI-Enabled Landscape Analysis | Pauline Flajolet | |
| 118-PCR | Domain-Specific Factors Associated With Mental, Physical, and Global HRQoL Among Adults Reporting Depression in the EU5 | Megan Jones | |
| 118-HSD | Attitudes Towards Patient-Centered Rare Disease Care Among Physicians in Five European Countries: A Cross-Sectional Survey | Megan Jones | |
| 118-RWD | Real-World Utilization, Expenditures, and Cardiovascular Events Among Users of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in US Adults With Type 2 Diabetes | Albaraa Alwafi | |
| 119-HTA | Obtaining Key Estimates of Resource Use Associated with Hidradenitis Suppurativa Management: Results from a UK-Based Online Delphi Study | Louise Longworth | |
| 119-HPR | Real-World Persistence with Liraglutide (Saxenda) for Weight Management in Adult Patients | Rosealeen Barrett | |
| 119-CO | Age, Comorbidity, and Time to Treatment as Drivers of First-Line BTKi Utilization in Real-World Chronic Lymphocytic Leukemia (CLL): A NorstellaLinQ Analysis | Tori Rodgers | |
| 120-PCR | From Detection to Action: Using eCOA Monitoring Signals to Drive Targeted Intervention | Lindsay Hughes | |
| 121-RWD | Temporal Trends in ICD-10-CM Obesity Coding Accuracy, 2021-2025: Evidence from the NorstellaLinQ Linked Claims and EHR Database | Tori Rodgers | |
| 122-MSR | Confounding and Adjustment Concerns in External Control Arm Evidence submitted to IQWiG | Sarah Pytlak | |
| 122-CO | Real-world effectiveness of tepotinib monotherapy (tepotinib) versus pembrolizumab ± chemotherapy (pembro±CT) in 1L for patients with MET exon 14 skipping alterations in locally advanced or metastatic non-small cell lung cancer in the US | Mo Yang | |
| 123-RWD | One Concept, Many Cohorts: Impact of Cohort Phenotype Definitional Variance in Depression, Major Depressive Disorder and Treatment-Resistant Depression on Real-World Research | Katy Manni | |
| 123-CO | A match-adjusted indirect comparison (MAIC) of efficacy outcomes between lifileucel and ipilimumab (IPI) in anti-PD1 resistant advanced melanoma | Murat Kurt | |
| 124-RWD | Alcohol Use Disorder (AUD) Screening Follows Diagnosis Rather Than Preceding It: Evidence of Systemic Workflow Gaps from NorstellaLinQ Real-World Data | Tori Rodgers | |
| 124-EE | Economic Outcomes of Emicizumab in Managing Haemophilia A Among Children and Adults in the UAE: Monetization of a Retrospective Analysis Conducted at Tawam Hospital and Sheikh Khalifa Medical City | Alaa Farahat | |
| 124-CO | Comparative Effectiveness of Afami-cel in Synovial Sarcoma Using Unanchored Matching-adjusted Indirect Comparisons | Noemi Hummel | |
| 125-RWD | Disability and Functional Status Invisible in Claims: Capturing Longitudinal EDSS in Multiple Sclerosis With a Human-in-the-Loop Large Language Model Applied to NorstellaLinQ US Electronic Health Records | Tori Rodgers | |
| 125-PCR | Estimation of Meaningful Change Scores for the EQ Visual Analog Scale (EQ-VAS) in Patients With Tardive Dyskinesia | Jennifer Lautenbach | |
| 125-EE | Evaluating the Societal Burden of Psoriasis and the Indirect Cost Impact of Tildrakizumab in Europe: A Real-World Evidence-Based Modeling Study | Björn Schwander | |
| 126-HTA | Beyond Validation: A Conceptual Framework for Digital Endpoint Reimbursement & Assessment | Artem Boltyenkov | |
| 127-HSD | Artificial Intelligence And Health Inequity: A Targeted Literature Review Of Bias Arising From Historical Healthcare Data (2020-2026) | Tanha Ahmed | |
| 127-MSR | A Simulation Framework for Quantifying Structural Uncertainty in Claims-Based Rare Disease Prevalence Estimation | Astrid Genet | |
| 127-RWD | Feasibility of Constructing HR+/HER2- Metastatic Breast Cancer Cohorts Incorporating Treatment Sequencing in a Japanese Multicenter Oncology EMR Database | DIMITRA LAMBRELLI | |
| 128-RWD | Treatment Sequencing and Line-of-Therapy Patterns in the BTKi Era: Real-World Evidence from 24,410 Chronic Lymphocytic Leukemia (CLL) Patients Using NorstellaLinQ | Tori Rodgers | |
| 128-EPH | AI-Assisted vs. Manual Systematic Literature Review in Multiple Sclerosis Mortality: A Comparative Assessment | Juan Sebastian Pineda | |
| 128-HTA | Bridging EU and National HTA Dossiers: Challenges and Early Lessons from German Delta Dossier Development | Astrid Genet | |
| 129-RWD | Biomarker-Driven Treatment Patterns and Guideline Concordance in Advanced Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence from NorstellaLinQ Claims and EHR Data | Tori Rodgers | |
| 129-EE | The Cost-Effectiveness of Imlifidase for Desensitisation Treatment of Highly Sensitised Adult Kidney Transplant Patients in Spain | Ferran Perez | |
| 130-PCR | Establishment of the Importance of and Meaningful Change in Physical Activity in Patients with Cancer Cachexia; a DHT-Measurable Concept | Leila Lackey | |
| 130-HTA | National Implementation of the EU HTA Regulation: Evolving National Approaches Across Member States | Sarah Pytlak | |
| 130-EE | Modern Excel for Cost-Effectiveness Modelling: Efficiency Gains, Validation Challenges, and HTA Acceptability | Rachel Ryder | |
| 131-EE | A Cost-Utility Analysis of Initiating Patients on Peritoneal Dialysis Versus In-Centre Haemodialysis in the United Kingdom | Araadhna Sinha | |
| 131-RWD | A Framework for Evaluating the Robustness of External Control Arms in Ovarian Cancer via Generative Synthetic Simulation | Colleen Dumont | |
| 131-HPR | Institutional Implementation of ESMO-MCBS Value Assessment in Oncology Formulary Management: A Tertiary Healthcare System Study | Laila Carolina Abu Esba | |
| 132-EE | Financial Impact of Bundled Contracts in Hemodialysis: A Total Cost of Ownership (TCO) Case Study of a Region in Sweden | Sophie Boeger | |
| 132-CO | Comparative Effectiveness of Odevixibat Versus Maralixibat in Alagille Syndrome: A Modelling-Based Analysis of Pruritus Response, Durability, and Long-Term Patient-Relevant Outcomes | Daniela Patrascan | |
| 135-PCR | Researching the Burden of Netherton Syndrome: A Systematic Literature Review | George Morgan | |
| 136-EE | Cost-Effectiveness Analysis of Adjuvanted RSVPreF3 OA Vaccine in Adults Aged =75 Years and the Comorbid Population Aged 60-74 Years in Switzerland | Costello Medical | |
| 136-HPR | Five Years of the FIFARMA W.A.I.T. Indicator: A Longitudinal Analysis of Oncology and Orphan Drug Access in Latin America (2022-2026) | Carmen Silvana Lay Ma | |
| 137-HTA | A Mapping Gap in the New UK EQ-5D-5L Era: Implications for Health Technology Assessment | George Bungey | |
| 137-EE | Modelling Multi-Dose Malaria Vaccine Implementation In Nigeria: Insights From National Vaccine Dose Progression Patterns | Franklyn Opara | |
| 137-PCR | A Real-World, Global Survey of the Disease Burden of Treated Hemophilia B Male Patients. | Maria Gheorghe | |
| 137-EPH | How Data Source Choice Affects Healthcare Utilization and Cost Estimates: Comparing National and Regional Data in Sweden | Kelvin Kwok | |
| 138-MSR | Accelerating RWE Treatment Pattern Synthesis Through AI-Assisted Literature Review | Shreya Dam | |
| 138-HTA | The Last Mile of Access: First-Use Adoption of Innovative Hospital Medicines After National Funding Approval in Portugal | Hugo Pedrosa | |
| 138-EPH | Epidemiology of Amyotrophic Lateral Sclerosis (ALS) Among Adults in Spain: A Systematic Review, Meta-Analysis and Future Projections | Leah Moore | |
| 139-HTA | Impact of Most Favored Nation (MFN) policy changes: survey of payer insights | Craig Tallentire | |
| 140-EE | Cost Implications of Declining MMR Coverage in England: A Two-Cohort Analysis of NHS Burden and Catch-Up Vaccination Value | George Bungey | |
| 140-PCR | Impact of Comorbidity Burden on Long-Term Quality of Life Following Severe Viral Lower Respiratory Tract Disease Hospitalisation | Rebecca Hardy-Woods | |
| 141-RWD | Work Productivity and Activity Impairment in Huntington´s Disease: Evidence from the UK | Ioannis Tomazos | |
| 142-MSR | Comparative Validation of Survival Extrapolation using Parametric Models for Health Economic Evaluations | Sarah Pytlak | |
| 143-HPR | The Evolving Access and Policy Concerns of Global Pharmaceutical Manufacturers: An Analysis of Challenges and Policy Solutions Identified in Manufacturers´ Comments in Response to International Reference Price-Based Proposals | Emma Hammer | |
| 143-EPH | Utilisation of inhaled therapies for maintenance treatment of chronic obstructive pulmonary disease in Ireland: a retrospective analysis of primary care claims data | Amelia Smith | |
| 143-MSR | Longitudinal Adherence Patterns of Asciminib versus Other Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Group-Based Trajectory Analysis | Gabriel Marquez | |
| 144-RWD | Case determination in Wilson´s disease: a population-based study of mortality and long-term outcome in the French national insurance claims | Sarah Pytlak | |
| 145-PCR | PROMs in long-COVID and ME/CFS/post-viral fatigue: analysis of study records from the past 2 years (2024-2026) | Kathleen Bowes | |
| 145-HPR | Impact of Measurement Error and Differential Misclassification on Assessments of Hospital-Based Surgical Quality | David Etzioni | |
| 146-CO | Weight Loss Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) When Used with and without Lifestyle Modifications: A Retrospective Real-World Study | Janna Manjelievskaia | |
| 146-EPH | Patient Characteristics and Treatment Persistence Among Early Adopters of Bimekizumab: A Swedish Registry-Based Cohort Study in Patients with Psoriasis | Meg Smith | |
| 146-PCR | Psychological and Interpersonal Impacts of Plaque Psoriasis: a Qualitative Social Media Analysis | Jessica Dunne | |
| 147-RWD | Population characteristics, healthcare resource use and costs of Hidradentis Suppurativa in France - The HESTIA study | Costello Medical | |
| 148-CO | Clinical Burden of Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Systematic Literature Review | Atish De | |
| 148-MSR | PERSONALIZED VERSUS GENERAL MULTI-CANCER DETECTION - AN EXPLORATORY, SIMULATION-BASED, BURDEN-BENEFIT ANALYSIS | Reinier Meester | |
| 148-EPH | Increased rates of emergency care in people with idiopathic inflammatory myopathies: A population-based cohort in England 2002 to 2021 | Charlotte Curtis | |
| 148-PCR | Preferences and Willingness-to-Pay for Lyme Disease Vaccines in the United States: A Latent Class Approach | MARCO BOERI | |
| 149-CO | Health-Related Quality-of-Life in Patients with Rare Mold Infections: EQ-5D-5L Results from a Phase IIb Trial Evaluating Olorofim in Adults with Invasive Fungal Infections and Limited or No Treatment Options | Craig Coleman | |
| 150-MSR | Impact of Estimand Misalignment in Indirect Treatment Comparisons of Oncology Trials with Treatment Switching - A Simulation Study | Thilo Welz | |
| 150-RWD | BALANCING EFFICACY AND RESOURCE USE: A PRAGMATIC APPROACH TO PRURITUS MANAGEMENT IN DIALYSIS PATIENTS IN US DIALYSIS ORGANIZATION | Marco Soro | |
| 151-RWD | Transforming Pre-Launch Forecasting: An Agentic AI Platform for Transparent Scenario Planning in Pharma | Zeshan Ghory | |
| 151-EPH | What Form of RSV Prevention Do Women in Asia Prefer: Maternal Vaccination or Infant Immunisation? | Amanda Woo | |
| 151-PCR | Beyond Patient Outcomes - The Growing Recognition of Caregiver Impact in Outcomes Research | Céline Desvignes-Gleizes | |
| 152-RWD | Beyond Claims Data: A Legally Governed Integrated EHR-Claims Database for Real-World Evidence Generation in Japan | DIMITRA LAMBRELLI | |
| 152-MSR | Structuring Value Elements for Cost-Effectiveness Modelling: The STEPPS Framework Applied to Fazirsiran in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease | Samantha Branton | |
| 153-HTA | PICO Provenance Evaluating AI Traceability for EU Joint Clinical Assessments | Katherine Gibbs | |
| 153-PCR | Standardizing Personalized Outcome Assessment with Goal Attainment Scaling: Reliability of a Structured Goal Appraisal Framework and Evaluation of AI-Assisted Review | Rebecca Metcalfe | |
| 153-MSR | Phenotyping Tenosynovial Giant Cell Tumor (TGCT) at Population Scale: Validated Large Language Model (LLM) Extraction From US Real-World Clinical Notes | Tori Rodgers | |
| 154-PCR | Developing Evidence-informed Patient Engagement Guidance for Economic Evaluations (DEEP-ENGAGE): Findings from a Scoping Review and an International Survey | Kednapa Thavorn | |
| 154-RWD | Scaling a US-Validated Automated Registry Model to Europe: Using National Digital Health Maturity as a Market Readiness Framework for Site-Level Real-World Evidence Generation | Ombretta Palucci | |
| 154-HTA | Is There an Implicit Cost-Effectiveness Threshold in France? Evidence from CEESP Assessments (2021-2026) | Colleen Dumont | |
| 154-HPR | Dual brand strategy in German drug pricing: limited opportunity based on AMNOG framework with exceptions? | Lina Hohmann | |
| 155-HPR | Potential Impact Of U.S MFN Pricing on Ex-US Product Launch and Withdrawal Strategies | Mackenzie Mills | |
| 156-RWD | Real-World Use and Discontinuation of Hypertension Therapies: Insights from the EnligHTN Study Using Primary Care Data in Italy | Bianca Oresta | |
| 156-PCR | Capturing Real-World Patient Experience: Cross-Indication Validation of an LLM Social Media Listening Pipeline Without Retraining | Natalia Hawken | |
| 157-RWD | Ambulatory Cardiac Monitoring Utilization and Guideline Alignment Among Symptomatic Arrhythmia-Naive Patients in England: A Real-World Evidence Study | Ramaa Nathan | |
| 157-EE | Global Economic and Humanistic Burden of Severe Hypertriglyceridemia: A Systematic Literature Review | Michelle Po | |
| 157-MSR | The Sensitivity Analysis Paradox in Target Trial Emulation: An Empirical Taxonomy of Bias Mitigation and Protocol Design in 208 Studies | Alban Fabre | |
| 158-MSR | An LLM Agent Builds a Functional Cost-Effectiveness Model in Excel with Live Formulas and VBA Macros from a Written Specification: A Novel Architectural Approach | Andre Verhoek | |
| 158-RWD | Comparative Efficacy and Safety of Orforglipron vs SGLT-2 Inhibitors for the Treatment of Insufficiently Controlled Type 2 Diabetes as an Add-On to Background Therapy of 1-2 Oral Antidiabetic Drugs: A Network Meta-Analysis | Mallory Ford | |
| 158-EPH | Counting What Counts; The Visibility of Health Policy and Equity in Health Economics Research: An Empirical Review | Colleen Dumont | |
| 158-PCR | Antihypertensive Prescribing Patterns and Blood Pressure Control in Adults with Food Insecurity: A Health Equity Analysis | Claire Campbell | |
| 159-MSR | MAPPING FOUNDATIONAL DECISION-AI METHODS IN HEALTH ECONOMIC EVALUATION: A SCOPING REVIEW | Archita Sarmah | |
| 159-HTA | From Medical Writer to Medical Editor: Redefining the Role of HTA Professionals in the Age of AI-Assisted Document Development | Katharina Hoffmann | |
| 159-PCR | Patient Reported Outcomes Associated With Non-Treatment: A Real-World Outcomes Evaluation of Atrial Fibrillation Patients Not Receiving Oral Anticoagulation | Ali Siddiqui | |
| 160-EE | Cost-effectiveness of bempedoic acid as adjunct to standard of care (SOC) therapy in Australia for the treatment of adults with hypercholesterolaemia classified as either high-risk primary or secondary prevention. | Joshua OMalley | |
| 161-RWD | Systematic Variation in ICD-10-CM Obesity Coding by BMI Severity, Sex, and Age: Evidence from the NorstellaLinQ Linked Claims and EHR Database | Tori Rodgers | |
| 162-HTA | From approval to access: time to reimbursement decision for biosimilars in the EU-4 | Katherine Gibbs | |
| 162-CO | Uptake of FLT3 inhibitors and impact on overall survival in patients with Acute Myeloid Leukemia in Sweden | Kelvin Kwok | |
| 162-EE | Health State Utilities For Clinical Events In Atrial Fibrillation: A Systematic Review | Maria-Magdalena Balp | |
| 163-HPR | ASSESSING THE IMPACT OF US MFN POLICY ON EMA APPROVAL TIMING FOLLOWING FDA APPROVAL: AN EXPLORATORY ANALYSIS | Tracey Tingle | |
| 164-RWD | Same Concept, Different Cohort? Comparing Diagnosis Code-Based (Claims) and PHQ-9-Based (Specialty EMR) Operational Definitions of Depression in Real-World Data | Katy Manni | |
| 164-CO | Real-world effectiveness of MET TKIs versus pembrolizumab ± chemotherapy (pembro±CT) in 1L for patients with MET exon 14 skipping alterations in locally advanced or metastatic non-small cell lung cancer in the US | Mo Yang | |
| 165-RWD | Clinical Identification and Management Patterns in Alcohol Use Disorder (AUD): Evidence from NorstellaLinQ Structured and Human-in-the-Loop Large Language Model (LLM) Extracted Clinical Data | Tori Rodgers | |
| 165-PCR | A Social Media Listening Analysis of Perceived Health Improvements Associated with Glucagon-like Peptide-1 (GLP-1) Use Beyond Weight-loss and Diabetes-focused Communities | Megan Jones | |
| 167-EPH | Impact of baseline comorbidities and combinations of comorbidities among people with type 2 diabetes on health care resource utilisation in the UK | TARIQ HALASA | |
| 167-CO | Efficacy and Safety Evidence Associated with First-Line Treatments for Patients with PD-L1 ≥50% Advanced NSCLC: A Systematic Literature Review | Natalie Polsky | |
| 167-RWD | Real-World Comparator Evidence for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Derivation of an NHS England Registry Cohort to Support Indirect Comparative Effectiveness Analyses | Marie Hutchinson | |
| 168-MSR | Evaluation of an AI-augmented literature review platform in targeted literature reviews - a practical industry HEOR perspective | Jack Timmons | |
| 168-PCR | A Decade of the Recovering Quality of Life (ReQoL) Questionnaire: Uptake and Use of a Recovery-Oriented Quality of Life Measure in Mental Health Clinical Research | Colleen Dumont | |
| 169-RWD | Real-World Clinical Indicators Prior to First-Line Treatment Initiation in Chronic Lymphocytic Leukemia (CLL): A NorstellaLinQ Claims and EHR Analysis | Tori Rodgers | |
| 169-EE | Identical outputs, divergent defensibility: LLM interaction style in health-economic modelling | Anand Jacob | |
| 170-EE | C-Peptide-Based Economic Model for Evaluating Tregs plus Rituximab in Recent-Onset Type 1 Diabetes | Diana Teloian | |
| 170-PCR | Health Utility and Work Productivity Burden Associated With Co-Occurring Anxiety and Chronic Pain Among Adults Reporting Depression in the EU5 | Megan Jones | |
| 172-HPR | Regulatory Reality versus Measurement Ambition: Clinical Outcome Assessments (COA) and Concept Coverage in Obesity Labels and Guidelines across FDA and EMA | Tilly Stott | |
| 172-PCR | Parent-Child Agreement in Pediatric HRQoL Measured by PedsQL: Differences by Disease Chronicity and Context | Marcelo Alves Favaro | |
| 173-HPR | Tackling Socioeconomic Inequalities Associated With Meningitis And Encephalitis And The Role Of Rapid Multiplex Testing | Hayden Holmes | |
| 173-EPH | Untreated risk of hospitalization and death among high-risk patients with mild-to-moderate COVID-19 in the United States: a systematic literature review update | David Campbell | |
| 173-RWD | Cross-Country Differences in Real-World Laboratory Monitoring Intensity and Hepatotoxicity Adverse Event Detection Among Initiators of CDK4/6 Inhibitors for Advanced Breast Cancer | Darren Johnson | |
| 174-MSR | Doing More with Less: Strategies to Reduce the cost of Generative AI in HEOR | Marcus Read | |
| 174-CO | Tumor stabilization and long-term IGF-1 normalization rate with pasireotide LAR and pegvisomant in real-world second-line acromegaly treatment | Sika Dede Kossi | |
| 175-RWD | Assessment of Real-World Treatment Patterns and Survival Outcomes of Small Cell Lung Cancer Patients in England Utilising the English Cancer Registry Data | Tijana Stanic | |
| 176-RWD | Closing Gaps in Real-World Evidence: Unlocking Clinical Value from Unstructured EHR Notes | Zuzana Dostalova | |
| 177-HTA | A MULTI-SCALE CLASSICAL AI FRAMEWORK FOR SYSTEM-LEVEL VALUE ASSESSMENT OF HEALTH TECHNOLOGY ADOPTION | Archita Sarmah | |
| 177-PCR | Patient and Caregiver Preferences for Rapid and Early Seizure Termination (REST): Qualitative Interviews and Quantitative Survey in Europe | Lorna Greenaway | |
| 178-HPR | Provisional and Time-limited Access Pathways - A Comparative Analysis of Canada, UK, EU, and Australia | Jasim Uddin | |
| 178-PCR | Patient Preferences in Neuromyelitis Optica Spectrum Disease (NMOSD): A Swing Weighting Study | Moushmi Singh | |
| 179-HTA | Methods for modelling immature overall survival (OS) in breast cancer (BC) in National Institute for Health and Care Excellence (NICE) technology appraisals (TAs) | Chloe Spalding | |
| 179-PCR | Patient Experience With Bladder-Sparing Therapy in Muscle-Invasive Bladder Cancer: A Targeted Literature Review | Allison Thompson | |
| 180-RWD | Caregiver Burden in Huntington´s Disease: Impact on Quality of Life and Work Productivity in the UK (HDBOI Study) | Ioannis Tomazos | |
| 180-CO | Matching-Adjusted Indirect Comparison: Rozanolixizumab Versus Nipocalimab in Generalized Myasthenia Gravis | Adam Hall | |
| 180-EE | Estimating Individual-Level Medical Cost Savings from Digital Chronic Disease Management: A Biometric-to-PMPM Proxy Methodology | Yifat Fundoiano-Hershcovitz | |
| 181-RWD | A Population-Based Data Linkage Approach to Study Fetal and Neonatal Alloimmune Thrombocytopenia: Overcoming Data Fragmentation | Kelvin Kwok | |
| 182-RWD | A Novel Registry-Database Linkage to Enable Real-World Evidence Generation in Rare Diseases: Algorithm Development and Validation for Myotonic Dystrophy Type 1 in the French SNDS | Nadia Quignot | |
| 182-PCR | Humanistic Burden Of Cachexia In Gastrointestinal Cancers: A Systematic Literature Review | Anand Jacob | |
| 183-CO | Bridging Animal and Owner Perspectives: Linguistic Validation of Companion Animal Quality of Life Measures Thaisa Lucas Sandri, DVM MSc PhD, Senior Scientific Manager, Zoetis Axelle Nadjar, Account Services Manager, Language Services, ICON Lara Salmassi, | Axelle Nadjar | |
| 183-MSR | Human Versus Artificial Intelligence for Data Extraction in Systematic Literature Reviews: A Review of Accuracy, Efficiency, and the Evolving Role of Human Reviewers | Xuan Wang | |
| 184-HPR | Healthcare Resource Utilization and Costs in HR+/HER2- Breast Cancer: Evidence from Mexico | Leticia Cuapio | |
| 185-CO | Maintaining Conceptual Equivalence in Linguistic Validation for Linguistically Underserved Languages: Challenges and Practical Solutions from Lao, Khmer, Tigrinya, and Kinyarwanda | Elinor Rees | |
| 185-EPH | Deriving Clinically Plausible IDH-Mutant Low-Grade Glioma Cohorts from German Claims Data Using a Multi-Stage Algorithm | Lisa-Marie Müller | |
| 185-PCR | How Does Cachexia Influence Health-Related Quality of Life Burden Among Adults with Solid Tumor Cancers in the United States and Europe? | Patrick Hlavacek | |
| 186-RWD | Enriching Real-World Treatment-Pattern Analysis in Overactive Bladder by Linking NorstellaLinQ Claims With NorstellaLinQ Electronic Health Record Notes Using Manual Clinical Review | Tori Rodgers | |
| 186-HTA | Deep Characterization of Clinical Trial Populations: Benchmarking a High-Granularity Generative Artificial Intelligence Framework for EU Joint Clinical Assessments | Colleen Dumont | |
| 187-HTA | PICO Divergence and Evidence Feasibility in EU Joint Clinical Assessments: Insights from Published Scoping Exercises and the First Tovorafenib Assessment | Gabriela Mendoza | |
| 187-CO | Estimating the Health Impact of Intensifying Lipid-Lowering Therapy in Patients at Risk for or Diagnosed With Atherosclerotic Cardiovascular Disease in Denmark | Emilie Theisen Honore | |
| 189-RWD | Prevalence of potentially inappropriate prescribing (PIP) in older adults in 2025 in the United States: Can we do better in the digital age? | Kathryn Evans | |
| 190-RWD | A Hybrid, Multi-Source Real-World Evidence Framework for Post-Authorization Studies: Design Considerations for EU Joint Clinical Assessment Readiness | Ombretta Palucci | |
| 191-CO | Impact of semaglutide versus tirzepatide on weight and body mass index in patients with polyendocrine metabolic ovarian syndrome (PMOS): analysis of US real-world data | Janna Manjelievskaia | |
| 191-HTA | Strengthening Comparative Evidence for HTA: A Structured causal framework for confounder identification | Sophie Wang | |
| 192-MSR | Automating R Shiny Cost Effectiveness Models for Stroke Using a Multi Agent AI Framework: Development and Validation | Sridhar Banerjee | |
| 193-CO | Indirect Treatment Comparison of Orforglipron and Oral Semaglutide in Japanese Patients with Type 2 Diabetes | Martin Petrillo | |
| 193-HPR | Creating Blueprints in Value-Based Procurement (VBP): The Case of Dialysis | Sophie Boeger | |
| 194-PCR | Assessing the health-related quality-of-life burden of lipoprotein apheresis in paediatric homozygous familial hypercholesterolaemia | Laura Cornic | |
| 195-EE | Persistent Productivity Loss and Disease Activity-Related Indirect Costs in Inflammatory Arthritis: 10-Year Real-World Evidence from Rheum4U Registry | Cassandra McLaughlin | |
| 195-MSR | Closing the Language Gap in HEOR Reviews: Validating AI-Assisted Screening of Chinese-Language Evidence | Caroline von Wilamowitz-Moellendorff | |
| 197-HTA | Burden of Restricted and Inequitable Access in Rare Disease: Global Effects (BRIDGE) Study | Tom Allen | |
| 199-CO | Definition and Assessment of Infant Neurodevelopmental Delays in Pregnancy Studies: An AI-Assisted Targeted Literature | Niamh McGuinness | |
| 199-EPH | Structural Patient Safety Failures in Non-Medical Aesthetic Settings: Evidence From a Nationwide Dermal Filler Inspection Program in Switzerland to Inform Risk-Based Regulatory Policy | Anita Kuduzovic | |
| 200-CO | Characterizing the Clinical and Humanistic Burden of Myelofibrosis: Evidence From a Systematic Literature Review | Andrii Danyliv | |
| 200-MSR | Controlling for What Comes Next: Estimating Generalized Direct Effects of First-line Therapy on Real-world Overall Survival Using Counterfactual Second-line Distributions in Advanced Non-small Cell Lung Cancer | Darren Johnson | |
| 201-PCR | The hidden patient burden in alopecia areata and vitiligo: identifying gaps in routine data capture | Fiona Glen | |
| 201-EE | Cenobamate Versus Vagus Nerve Stimulation and Epilepsy Surgery in Focal Drug-Resistant Epilepsy: A Cost-Comparison Analysis in the UK NHS | Giorgio Di Dato | |
| 201-CO | Real-World Treatment Patterns and Clinical Outcomes in Previously Untreated Locally Advanced or Metastatic Triple-Negative Breast Cancer, by PD-L1 Status: A NorstellaLinQ US Linked Claims-EHR Study | Tori Rodgers | |
| 202-MSR | Agreement Between Artificial Intelligence and Human Assessment in Quality Appraisal of Economic Evaluations Using the Drummond Checklist | Caitlyn Matuska | |
| 203-HTA | Fit for Prevention? Vaccines Under the European Union Joint Clinical Assessment Framework: a Targeted Literature Review | Caitlyn Matuska | |
| 203-MSR | Identification Of Treatment Effect Modifiers (TEMS) And Prognostic Factors (PFs) In Matching-Adjusted Indirect Comparisons (MAICS)- A Systematic Literature Review. | Stacey Chang-Douglass | |
| 203-PCR | Multi-country Content Validation of the EQ-5D-5L + 4 Bolt-on Items Within Non-segmental Vitiligo | Louise Longworth | |
| 204-EPH | Understanding Systemic Barriers to Vaccination in Low- and Middle-Income Countries | Craig Tallentire | |
| 204-HPR | Variables Influencing Competition in Dutch Medical Specialist Care | Jeroen Mulder | |
| 205-PCR | Spotlight on Sjögren´s: Disease Burden and Unmet Needs for Patients in Spain | Thomas Dewar | |
| 205-CO | Assessing the Public Health Impact of Dostarlimab for DMMR/MSI-H Advanced or Recurrent Endometrial Cancer in Brazil: QALY Results from a Brazilian Public Healthcare Perspective | Costello Medical | |
| 205-MSR | Investigation of the benefit of using an OS-prognostic biomarker for early decision making in oncology | Tim Becker | |
| 206-EE | Health utility values measured by EQ-5D in patients with Parkinson´s disease: a systematic review and meta-analysis | SOOBIN JANG | |
| 207-MSR | Feasibility Assessment of Network Meta-Analysis in Generalized Myasthenia Gravis: Methodological Challenges From a Rapid Evidence Review | Sridhar Banerjee | |
| 208-MSR | Quantifying Unmet Needs in Rare or Severe Autoimmune Diseases: Novel Study Design for a Cross-Indication Comparison of Patient and Physician Preferences | Kelly Wyatt | |
| 210-PCR | How can we Approach Whole Health Using Digital Biomarkers and Endpoints from Consumer Wearables? | Annette Champion | |
| 211-PCR | A Review of Goal Attainment Scaling Implementation and Reporting in Clinical Trials over the Last Decade | Rebecca Metcalfe | |
| 211-HPR | Most Favoured Nation Drug Pricing in the US: Why a National HTA Agency Is Needed Beyond International Reference Pricing | Gabriela Mendoza | |
| 211-HTA | Impact of Comparator Selection Based on Sequential Analysis on Cost-Effectiveness Conclusions in CDA-AMC Reimbursement Recommendations | Ana Rusu | |
| 213-EE | Treatment Patterns, Healthcare Resource Utilization and Costs among Patients with Tenosynovial Giant Cell Tumor (TGCT) in the United States | Carroline Lobo | |
| 213-HTA | Residual Confounding in Real-World External Control Arms: An Updated NICE Appraisal Review | Cormac Sammon | |
| 215-HPR | MFN Shockwaves Beyond the US: Evidence of Accelerated German Launches, Selective Non-Entry | Costanza Alciati | |
| 215-CO | Real-world (rw) clinical outcomes and correlation of recurrence free survival (RFS) and distant metastasis survival (DMFS) to overall survival (OS) in resected stage III-IV cutaneous melanoma | Yuexin Tang | |
| 215-EE | Cost Comparison of Isatuximab Subcutaneous, Isatuximab Intravenous, and Daratumumab Subcutaneous in Multiple Myeloma in Japan | Sarah Pytlak | |
| 217-HPR | Is Europe Becoming a Later Regulatory Launch Market? Trends in EMA Authorisation After FDA Approval | António Cardoso | |
| 217-PCR | The Use and Reporting of Conceptual Models for Attribute Development in Preference Research - Insights from a Scoping Review | Sofia Gonçalves | |
| 217-HTA | Patient Involvement in HTA Across the EU4 and UK: A Mapping of Access Points and Influence Across HTA Milestones | Evelien de Wilt | |
| 218-CO | Understanding Unmet Need in the Contemporary Treatment Landscape in a European Generalized Myasthenia Gravis Population from both Physician and Patient Perspectives: A Real-World Study | Sanal Simon | |
| 218-EE | Methodological Considerations for Economic Modeling in Pediatric Populations: A Targeted Literature Review | Jorge Fernando Nino de Rivera | |
| 218-EPH | Prevalence and Incidence of Adults with Severe Hypertriglyceridaemia and High Risk of Acute Pancreatitis (>880 mg/dL): A Systematic Literature Review and Meta-Analysis | Tyrone Daniel | |
| 218-MSR | Faster, Mostly Faithful: Can AI Reproduce Manual PICO Extraction in Preparation for EU JCA? | Milind Sood | |
| 219-MSR | A Mathematical Appraisal of the Family and Caregiving Effects Framework in Modelling Caregiver Spillover Effects | George Bungey | |
| 222-HTA | Applying a Framework to characterise the Evolution of Integrated Scientific Advice | Jennifer Boss | |
| 222-CO | Association Between Everolimus Time-in-Therapeutic Range and Nephrotoxicity in Adult Lung Transplant Recipients | Brandon McEwen | |
| 222-MSR | Development and Validation of an AI-Enabled Platform for Automating Systematic Literature Reviews: Multi-Agent Accuracy Assessment Across Screening and Data Extraction | Leah Moore | |
| 222-EPH | An NLP-based solution (REALLI) for RSV Case Identification and Clinical Characterization: A Retrospective Study in 13 French Hospitals (OMIP) | Laura MARTIN | |
| 223-MSR | The TSEipcw Method As An Alternative Solution To The Problem Of Treatment Switching | Birgit Neu | |
| 223-HPR | Estimating the Fiscal Cost of Stroke in the United Kingdom | Grace Mountain | |
| 224-EPH | Modelling the Impact of Scale-up of Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) for HIV Prevention inBrazil: A High-impact Investment in HIV Prevention | Thomas Bendall | |
| 224-CO | Real-world characterization of IPF and PPF patients in Spain: clinical features, diagnosis and HRQoL (RECOFIB study) | Alberto Cerdeño | |
| 224-PCR | Food Noise During Glucagon-like Peptide-1 (GLP-1) Maintenance: A Social Media Listening Analysis of UK Patient Communities | Megan Jones | |
| 225-CO | Content Validity and Psychometric Evaluation of the Urticaria Symptom Daily Diary (USDD) in Chronic Inducible Urticaria | Caitlyn Matuska | |
| 226-CO | Matching-Adjusted Indirect Comparison of Zilucoplan Versus Cemdisiran and Gefurulimab in Generalised Myasthenia Gravis (gMG) | Adam Hall | |
| 228-CO | Advancing Vaccine Value Assessment Through Cross-Study Antibody Kinetics Modeling: predicting long-term MenABCWY seroprotection | Robin Bruyndonckx | |
| 229-EPH | Real-world Characteristics and Advanced Therapy Use in U.S. Patients with Moderate-Severe Treatment Resistant Depression (TRD) | Marketing UBC | |
| 229-EE | First-Year Cost Comparison of FLAURA2 versus IV MARIPOSA in EGFR-Mutated Advanced NSCLC in Argentina | Marina Tabares | |
| 229-PCR | Health-Related Quality of Life Burden Associated With Past-Year Depression in the EU5: A Matched National Health and Wellness Survey Analysis | Megan Jones | |
| 230-PCR | ´Too Young for Care´: A Social Media Review of Age-Related Bias in Healthcare Settings | Caitlyn Matuska | |
| 230-EPH | Epidemiology and Treatment Pathways of Schizophrenia in England | Ravinder Claire | |
| 230-HTA | Indirect Treatment Comparisons in Dutch Health Technology Assessment: Evolving Methodological Expectations from 2017 to 2025 | Colleen Dumont | |
| 231-CO | Clinician Global Impression of Severity and Change Scales for Cutaneous Lupus Erythematosus: Cognitive Debriefing Evidence Supporting Clinical Utility | Paul Kamudoni | |
| 231-HPR | Balancing Ambition and Reality -The Shifting International Landscape of Performance-Based Managed Entry Agreements | Emma Kent | |
| 231-PCR | Health-Related Quality of Life in Patients with Chronic Diseases. A Targeted Literature Review of the Impact of Chronic Diseases in Spain and Europe | Ada Pelaez | |
| 232-MSR | The Best of Both Worlds? Hybrid Programmatic-AI Workflows for HTA-Grade Evidence Generation for Time-to-Event Analysis Interpretation and Reporting | George Bungey | |
| 232-PCR | Beyond Clinical Outcomes: A Patient and Family Co-created Value Framework to Capture the Full Impact of Chronic Childhood Disease | Brittany Gerber | |
| 232-EE | From PICO to Economic Evaluation: A Structured Framework for Aligning EU Joint Clinical Assessment (JCA) Evidence with National Economic Evaluations | Gabriela Mendoza | |
| 233-EE | The Impact of Mature Versus Immature Survival Data on Cost-Effectiveness Estimates in Oncology: A NICE Case Study | Anamaria Olivieri | |
| 234-EPH | Prevalence of Developmental and Epileptic Encephalopathies (DEEs) Among Patients with Epilepsy: A US Claims Analysis | Jessica Horrocks | |
| 236-EE | Economic Evidence Associated with First-Line Treatments for Patients with PD-L1 ≥50% Unresectable/Metastatic NSCLC: A Systematic Literature Review | Natalie Polsky | |
| 236-HPR | EARLY IMPACT OF MOST FAVOURED NATION (MFN) POLICY ON REIMBURSEMENT DECISIONS, LAUNCH ACTIVITY, AND MARKET ACCESS IN SWEDEN | Azad Saei | |
| 240-MSR | Development and Validation of the COmplication Model for obEsity and overweighT (COMET): A Patient-Level Stochastic Microsimulation Model for Obesity-Related Complications and Mortality | Lizheng Shi | |
| 240-EE | Early Economic and Pathway Impact of Incorporating Novel Mass Spectrometry-Based Testing into Treatment Response Assessment for Multiple Myeloma | Gregory Price | |
| 241-EPH | Estimating the PARP inhibitor-eligible population and market opportunity in ovarian, breast, and prostate cancer across EU15 | Nishant Kumar | |
| 241-EE | Age of disease causal human papillomavirus (HPV) infection for oropharyngeal cancer in Finland and Poland: a modeling study | Ugne Sabale | |
| 243-PCR | Determination of Meaningful Within-Patient Change Thresholds (MWPC) for the Functional Assessment of Cancer Therapy-Gastric (FACT-Ga) from STAR-221 Trial | Mira Patel | |
| 243-HTA | What Drives Positive NICE HealthTech Decisions? A Review of Economic Evaluation Evidence from Recent Appraisals | Vladislav Berdunov | |
| 244-PCR | Determining meaningful within-patient change thresholds for GODDESS outcomes in the Phase 3 RINGSIDE Part B trial | Samantha Fowkes | |
| 244-EPH | Real-World Burden of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Italy: Epidemiology, Treatment Patterns, and Healthcare Costs | Lisa Giannessi | |
| 245-EE | Economic Evaluation Of Sparsentan Versus Targeted-Release Formulation Budesonide In Patients With Primary Immunoglobulin A Nephropathy In Austria | Antonio Ramirez de Arellano | |
| 246-HTA | Expanded Value Measures through Behavior Change: An International Delphi Consensus on Reimbursement of Digitally Enabled Behavioral Interventions | Andrew Kwist | |
| 246-MSR | Internally Validated Prediction of Severe Health Utility Impairment Among Adults Reporting Depression in the EU5 | Megan Jones | |
| 247-PCR | Real-World Disability and Burden Among Patients with Chronic Inflammatory Demyelinating Polyneuropathy | Yasmin Taylor | |
| 249-PCR | Health-Related Quality of Life and Health-state Utilities in IgA Nephropathy: A Systematic Literature Review | Mark Pletscher | |
| 249-MSR | A Hybrid AI-Assisted Screening Framework for Systematic Literature Reviews in Acute Ischaemic Stroke-Large Vessel Occlusion: Efficiency and Accuracy | Sanal Simon | |
| 250-EE | Long-term economic impact of gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B in Spain | Miquel Sastre-Belío | |
| 250-PCR | Utility Generation for Sanfilippo syndrome type A (MPS IIIA) Using Health-State Vignettes | Simon Dawson | |
| 250-HTA | Health-Related Quality of Life Outcomes in Psychedelic-Assisted Therapy Trials for PTSD: A Rapid Review | Gabriela Mendoza | |
| 251-MSR | Mind the Data Gap: A Conceptual Framework for Proxy-Based Healthcare Cost Estimation in Europe | Rachel Ryder | |
| 251-HTA | Fifteen Years of German HTA (AMNOG): Trends and Drivers of "No Added Benefit" | Paul Bussilliat | |
| 251-EPH | Health outcomes by Chronic Obstructive Pulmonary Disease (COPD) diagnosis status and risk level: findings from the EU National Health and Wellness Survey | Megan Jones | |
| 256-HTA | Capturing the Patient Perspective: Targeted Literature Review Findings on the Critical Role of PROs in Oncologic AMNOG Evaluations | Caroline Protze | |
| 256-EE | Clinical and economic outcomes among patients with severe eosinophilic asthma who switched from mepolizumab to benralizumab from a United States healthcare system perspective | Andre Verhoek | |
| 257-PCR | Measurement Properties of the Patient-Reported Impact of Dermatological Diseases (PRIDD): A Global Study of Patients with Alopecia Areata | Allison FitzGerald | |
| 259-EE | Healthcare Resource Utilization in Patients with Severe Asthma treated with tezepelumab in Spain. Insight from the T-ROSS II study | Marta Alegria | |
| 259-PCR | Clarity Through Contrast: Elevating Stakeholder Insights from eDelphi Methods with a Patient-Centered Multi-Panel Design | Megan Jones | |
| 259-MSR | Performance of AI-Assisted Data Extraction Across Economic Systematic Literature Review Categories: A Case Study in Chronic Lymphocytic Leukaemia | Caitlyn Matuska | |
| 261-PCR | Translation Quality as an Underrecognized Determinant of Data Validity in Multinational HEOR: A Conceptual Framework | Alexander Vareiko | |
| 262-EE | Economic Positioning Of Surgery With Absorbable Steroid-Eluting Sinus Implants Versus Dupilumab In Severe CRSwNP : An Italian National Health Service Payer Perspective | Elisa Tacconi | |
| 263-MSR | Extending the Validation of Accuracy for Large Language Model (LLM)-/Machine Learning (ML)-Extracted Information and Data (VALID) Framework Globally: Quality Assessment of LLM-Derived Prostate Cancer Real-World Data in the UK | Darren Johnson | |
| 264-HTA | Exploring the Impact of Evolving Treatment Pathways on Comparator Relevance in European Oncology Health Technology Assessments (HTAs) | Evelien de Wilt | |
| 264-HPR | The Impact of Brexit on Pharmaceutical Regulation and Approval in the UK | Matthias Hofer | |
| 265-MSR | From Real-World Data (RWD) to In-Silico Design: An Integrated Approach to Optimise Study Design and Decision Making | Saimithra Thammera | |
| 267-EE | Cost-Effectiveness of Adding Intermittent Pneumatic Compression to Pharmacological Thromboprophylaxis After Total Hip and Knee Arthroplasty: A French Health-System Analysis | Sheila Fernandes | |
| 269-EE | Budget and Environmental Impact Analysis of Multi-layer Watertight closure versus Conventional Closure in Total Joint Arthroplasty in Spain | Leticia Sánchez Martín | |
| 274-MSR | Behind the Comparison: Are Feasibility Assessments Adequately Reported in Published ITCs? | Allie Cichewicz | |
| 275-MSR | From PICO to Dossier: Evaluating a Source-Grounded Evidence-Validation Layer for Evidence Traceability and Contradiction Detection in HTA-Ready Claims | Leah Moore | |
| 275-EE | Budget Impact Analysis of Obinutuzumab for Active Lupus Nephritis from the Brazilian Private Healthcare System Perspective | Natalia Bergamelli Ramos | |
| 277-MSR | XLGEN: A Structure-First Knowledge Graph Framework for AI-Assisted Quality Control of Excel-Based Budget Impact Models | Behnam Sharif | |
| 278-EE | Healthcare Burden Across UACR And Kidney Function Categories In Chronic Kidney Disease: A Real-World Study In England (The PROMISE Study) | Kaliya Hanman | |
| 280-MSR | Performance of Nested Knowledge Criteria-Based Screening and Adaptive Smart Tagging Against a Manually Conducted Systematic Literature Review in Hereditary Angioedema | Trisha Whitney | |
| 282-EE | Public Health and Economic Impact of Strategies to Protect Infants in the US against RSV | Mary MacKinnon | |
| 284-HTA | Acceptability of Indirect Treatment Comparisons in Orphan Versus Non-Orphan NICE Technology Appraisals | Dominic Muston | |
| 286-HTA | Impact of the 2026 UK EQ-5D-5L Value Set on Utility Estimates in Lupus Rash and Cutaneous Lupus Erythematosus | Praneetha Chaphekar | |
| 288-MSR | Configuration over content: how large language model settings, not question complexity, govern reference fabrication in narrative-review-style outputs | Allie Cichewicz | |
| 289-EE | COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINATION STRATEGIES IN OLDER ADULTS IN VIETNAM: A DYNAMIC TRANSMISSION MODEL ANALYSIS ACCOUNTING FOR CHILDHOOD VACCINATION EFFECTS | Ba Khuong Cao | |
| 291-MSR | Challenges for the Economic Evaluation of Diagnostic Technologies: a Review and Taxonomy | Ulises Garay | |
| 293-MSR | Are Biopharma Decisions Based on High-Quality RWE? Insights From SLRs | Anand Jacob | |
| 294-EE | An End-to-End LLM Pipeline for Health Economic Technical Reports: Rights-Verified Sources, Expert-Approved Drafting, and Hallucination-Free Citations | Andre Verhoek | |
| 295-MSR | Agentic artificial intelligence as a co-developer of health economic models: application to a cost-effectiveness analysis in adult attention-deficit/hyperactivity disorder (ADHD) | John Cook | |
| 295-HTA | Who Gets HTA´s Attention? Reclaiming Efficiency in Austerity | Christian Suharlim | |
| 296-EE | Clinical, Economic, and Humanistic Burden of Elevated Lipoprotein(a) in Patients with Atherosclerotic Cardiovascular Disease A Systematic Literature Review | Eduard Sidelnikov | |
| 296-HTA | Accepted, Revised, Rejected - Target Population Estimates in German Health Technology Assessment | Astrid Genet | |
| 297-EE | Quality-Adjusted Life Expectancy (QALE) by Ethnicity in England: Updated Estimates Using the New EQ-5D-5L Value Set | Jamie Kattle | |
| 300-HTA | Frequency and Acceptability of Severity Modifier in NICE Technology Appraisals | Ewa Rupniewska | |
| 302-EE | Health-related quality of life of informal carers: evidence from the Health Survey for England | Stacey Chang-Douglass | |
| 306-HTA | Current and Future Adoption of Artificial Intelligence by European Payers | Jordi Coste Pradas | |
| 310-EE | Long-term dementia risk reduction may improve the cost-effectiveness of blood pressure lowering interventions including renal denervation | Anne Ryschon | |
| 311-HTA | Integration of Patient-Reported Outcomes in Reimbursed Medicines in Italy (2020-2025): Implications for HTA and Innovativeness Assessment | Lucia Piampiani | |
| 312-HTA | Integrating environmental externalities into economic evaluation: a case study based on a French HTA assessment | Sarah Pytlak | |
| 313-HTA | Organizational Impacts in Health Technology Assessment: A Decision Framework for Evidence Generation | Olivier Marcellin | |
| 314-EE | Cost Effectiveness and Health Care Resource Utilization of Pre-emptive Use of TIPS with Controlled Expansion for High-Risk Patients with Variceal Bleeding in Italy | Geraldo Tadinho Monteverde Spencer | |
| 316-HTA | The Rise of China - Are Chinese Medicinal Products Successfully Launching in Europe? | Paula Skowron | |
| 319-EE | Test, Target, Treat: Cost-Effectiveness of hsCRP-guided treatment in people with atherosclerotic cardiovascular disease and chronic kidney disease in Sweden | Phillip Kittel | |
| 322-EE | Economic Burden of Obesity: Real-World Data from the Greek Private Healthcare Sector | KATERINA VOGIATZI | |
| 322-HTA | EU-HTA for Medical Devices: Risks, Opportunities, and Strategic Implications | Astrid Genet | |
| 324-HTA | Should The Efficiency Verdict Depends On The Chosen Reference Value? A Retrospective Analysis Of 2025 French CEESP Cost-Effectiveness Opinions | Stéphane Roze | |
| 324-EE | Economic Evaluation of Anti-Obesity Treatments; a TLR on modelling approaches | Colleen Dumont | |
| 330-EE | Lifetime Cost of Care Simulation of Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis | Yestle Kim | |
| 330-HTA | Regulatory/HTA framing Patient-Reported Outcome Instruments in Ulcerative Colitis Clinical Trials: Frequency of Use and Psychometric Evidence | Allie Cichewicz | |
| 333-EE | Quantifying the Societal Value of Resmetirom For Metabolic Dysfunction Associated Steatohepatitis Using a Societal Value Modeling Approach | Yestle Kim | |
| 333-HTA | Health Technology Assessment (HTA) Bodies (HTAb) Position On The Use Of Digital-Twin (DT)-Related Methodologies | Vincent Heller | |
| 334-EE | The Impact of Semaglutide on Hospitalization and Healthcare Costs in Israel | Udi Moshel | |
| 341-HTA | Drivers of Early Negative Appraisal Decisions Made by UK, France and Germany Health Technology Assessment (HTA) Bodies, and Strategies to Improve First-Time Decision Success: A Review of Solid Tumour Appraisals | Craig Tallentire | |
| 344-EE | Cost-effectiveness of oral nirmatrelvir-ritonavir in patients at high risk for progression to severe COVID-19 in the United States | David Campbell | |
| 347-EE | Cost-Effectiveness and Value-Based Price of CT-152 for Major Depressive Disorder in Japan: A Markov Model Analysis | Yilong Zhang | |
| 348-EE | Economic Impact of Bimekizumab for moderate to severe Plaque Psoriasis in France | Costello Medical | |
| 349-HTA | Real-World Evidence (RWE) Readiness for EU Joint Clinical Assessment: Gap Analysis Between Current RWE Studies and EU HTA Expectations | Neil Brett | |
| 350-HTA | HTA Bodies Request Fewer Than 50% of Guideline-Defined PICOs: Evidence from Eight EU Markets and Lessons for EU JCA | Paula Skowron | |
| 351-EE | The Cost per Responder of Bimekizumab versus Risankizumab in Psoriatic Arthritis (PsA) | Costello Medical | |
| 352-EE | Cost-per-Response of Advanced Therapies in Spondyloarthritis From the Perspective of the Brazilian Private Healthcare System | Thiago Marchesan | |
| 354-HTA | Examining NICE Cost-Effectiveness Thresholds Across Oncology and Non-Oncology Appraisals: Drivers of Decision-Making | Zuzanna Opuchlik | |
| 361-EE | The Economic Burden of Seizure Emergencies in Spain: Results from a Cost of Illness Study | Lorna Greenaway | |
| 363-HTA | Outcomes-Based Agreements in European HTA: Not a Routine Uncertainty Tool, but a Selective Access Mechanism | António Cardoso | |
| 364-EE | Budget Impact of an Enteral Feeding Pump Delivering Thick Formula (IDDSI 2-4) and Hydration to Support Blended Feeding in United Kingdom Paediatric Home Enteral Nutrition | Amandine Giraud-Sauveur | |
| 365-EE | Health and Economic Impact of Increasing Enteral Nutrition Use in Critically Ill Patients: Development of a Hospital-Based Value Communication Tool in Italy | Anamaria Olivieri | |
| 365-HTA | Are Rare Disease Clinical Trials Ready for EU Joint Clinical Assessment (JCA)? | Gabriela Mendoza | |
| 367-HTA | Teprotumumab for Thyroid Eye Disease: UK Key Opinion Leader Perspectives to Inform a NICE HTA Strategy | Salimah Champsi | |
| 368-EE | Clinical and Economic Burden of Metastatic Uveal Melanoma: A Retrospective Analysis of Commercially-insured, Medicare, and Medicaid Patients in the United States | Elizabeth Packnett | |
| 368-HTA | Health Inequalities in Women´s Health HTA: Are NICE Decisions Equity-Informed? | Fiona Glen | |
| 369-EE | Cost-Effectiveness and Pricing of AI Technology for Reading Mammograms in the England NHS Breast Screening Programme | Rachel Ryder | |
| 372-HTA | A framework approach to assess the evidence generation needs for two novel treatments in sickle cell disease preparing for UK health technology assessment: A case study | Marie Hutchinson | |
| 379-HTA | The Missing Stem of the Value Flower: HTA Implications When Real-World Value Depends on Supply-Constrained Health Systems | Christian Suharlim | |
| 380-EE | Socioeconomic burden of chronic lymphocytic leukemia in 43 European countries | Rachel Ryder | |
| 382-EE | Understanding the social value manufacturer revenue and reinvestment - a case study using palbociclib in HR+/HER2- advanced breast cancer | Marlon Graf | |
| 384-EE | Estimating Life-Year Gains of Tumor Treating Fields After First Progression in newly diagnosed Glioblastoma | Fernando Nino de Rivera | |
| 385-HTA | Joint Clinical Assessment, Evolving National HTA Guidance and Methods | Rachel Ryder | |
| 388-HTA | Are We READI for Disease-Specific Reference Case Extensions? Lessons from NICE´s Obesity Framework | Isobel Thornton | |
| 395-HTA | Capacity building or concentration? Early Patterns of Assessor and Co-Assessor Participation in European Union Joint Clinical Assessments | Lydia Vinals | |
| 396-HTA | Methodological reservations in recent French CEESP economic opinions: what characterises the most challenging submissions | Sarah Pytlak | |
| 399-HTA | What Do the First EU Joint Clinical Assessment Cohorts Reveal About Future Evidence Expectations? Early Insights for Manufacturers and HTA Stakeholders | Alexandra Guyenet | |
| 404-EE | A Simplified Treatment-Sequence Modelling Approach for Early Oncology Decision Support Using Limited Survival Data: A Case Study in Favorable-Risk Advanced Renal Cell Carcinoma | Andrea Berardi | |
| 404-HTA | Current GenAI Policy In HTA: The Missing Mandate And Implications For Industry | James Woolnough | |
| 406-EE | Cost-Utility Analysis of Sparsentan For the Treatment of Immunoglobulin A Nephropathy: a comparison of Sparsentan versus Irbesartan and Modified-Release Budesonide in Spain | Antonio Ramirez de Arellano | |
| 407-HTA | Towards Device-Focused Joint Clinical Assessment: Comparing Submission Templates for Medical Devices and Medicinal Products | Sophie Boeger | |
| 410-HTA | Supporting Evidence Generation Through Life-Cycle Scientific Advice: Five-Year Experience of Korea´s HTA Guide Programme | Wonji Ko | |
| 414-EE | Economic Model Architecture in NICE Evaluations for Ultra-Rare Non-Oncology Conditions: A Comparative Analysis of Structural Choices and Clinical Trial Endpoint Use Across the STA and HST Pathways | Anand Jacob | |
| 416-EE | Cost-effectiveness of recombinant human follicle-stimulating hormone combined with recombinant human luteinizing hormone (r-hFSH r-hLH) versus human menopausal gonadotropin (hMG) in ovarian stimulation for assisted reproduction in Germany | Claudia Roeder | |
| 419-EE | Economic and Operational Impact of a Fully Digital Diagnostic Pathway for Obstructive Sleep Apnoea in the NHS: A Time-Driven Activity-Based Costing Analysis | Ankit Ghildiyal | |
| 423-EE | Health and Economic Burden of Delayed Biologic Initiation in Severe Asthma:A Global Real-World Data-Informed Decision Model | Helena Emery | |
| 427-EE | Impact of Remibrutinib Treatment on Workplace Productivity Due to Chronic Spontaneous Urticaria (CSU): A Canadian Private Payor Perspective | Jacob Woodcock | |
| 430-EE | Conceptual Framework for Economic Modelling of Idiopathic Inflammatory Myopathies across Clinical Subtypes | Stacey Chang-Douglass | |
| 431-EE | Accounting for high placebo response in Health Technology Assessment: Evidence from NICE technology appraisals and lessons for RCTs and economic modelling for Sjögren´s disease | isabelle Lundqvist | |
| 438-EE | Kidney Transplant Reallocation: Quantifying Cost Savings and QALY Gains from Disease-Modifying Treatments for the UK NHS | Tyrone Daniel | |
| 439-EE | Budget Impact of RSVpreF Maternal Vaccine and Nirsevimab Monoclonal Antibody to Protect Infants in UAE against Respiratory Syncytial Virus | Mary MacKinnon | |
| 444-EE | Public Health and Economic Impact of Bivalent RSVpreF Vaccination Among Adults in Denmark | Mary MacKinnon | |
| 452-EE | Advancing Standardization in Digital Health: Integrating PICOTS-ComTeC and CHEERS-DHI to Improve Evaluation, Reporting, and Economic Assessment | Carl Asche | |
| 459-EE | Transforming the Assessment of Uncertainty in Health Economic Models Using Generative AI | Marcus Read | |
| 460-EE | Societal burden of atrial fibrillation: A nationwide cohort study in Sweden | Michael Hurst | |
| 461-EE | Cost-Effectivenessof the Symplicity Spyral™ Renal Denervation System in Adults with Uncontrolled Hypertension in Türkiye | Anne Ryschon | |
| 463-EE | The economic burden of syncope and specialist unit costs: a UK scenario and break-even analysis | Cristiana Monteiro | |
| 466-EE | Cost-Consequence Analysis of Covered Balloon-Expandable Stents with Published 3-Year Outcomes for Aortoiliac Occlusive Disease in the UK | Kashfa Iqbal | |
| 476-EE | Systematic Literature Review of the Economic Burden of Type 2 Diabetes in Italy: Cost Drivers Across Treatment-Defined Populations | Gaia Maria Luna Maglionico | |
| 482-EE | Projected Wider Societal and Fiscal Impact of Semaglutide in the United Kingdom | Robert King | |
| 484-EE | Nationwide Direct Healthcare Cost Burden of Documented Metabolic Syndrome in Slovakia: A Population-Based Cohort Study Using Administrative Healthcare Data | Tomas Mesaros | |
| 502-EE | Early Economic Evaluation of a Novel Orthotic Care Pathway for Hand Osteoarthritis. A Scenario and Threshold Analysis from an NHS Perspective | Victor Tapia | |
| 514-EE | Medication Cost Savings and Cost Avoidance From Clinical Pharmacist-Led Intravenous-to-Oral Conversion in Postoperative Surgical Patients at a Tertiary Cancer Centre in a Lower-Middle-Income Country | Adeel Siddiqui | |
| 515-EE | Important considerations in the selection of AI tools to support health economic model replication | Rachel Ryder | |
| 516-EE | Evaluating the Economic Impact of Adopting Selinexor-Based Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Qatar | Nancy Chidel | |
| 520-EE | The economic burden of Early-Stage HR+/HER2- Breast Cancer (BC) in Spain. A Cost-of-illness Study | Laura Ricou Ríos | |
| 524-EE | COMPARATIVE ANALYSIS OF MEDICAL COSTS AND HEALTHCARE RESOURCE UTILIZATION (HCRU) BETWEEN INTRAVENOUS (IV) AND SUBCUTANEOUS (SC) FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN BRAZILIAN PRIVATE ONCOLOGY PATIENTS: A RETROSPECTIVE REAL-WORLD STUDY | Flavia Tobaruella | |
| 528-EE | Beyond Cost-Effectiveness: Estimating the Social Value of Palbociclib Over its Lifecycle | Marlon Graf | |
| 529-EE | Real-terms depreciation of willingness-to-pay thresholds for double-branded oncology combinations across HTA markets, 2015-2025 | Ruodan Nan | |
| 530-EE | Estimated Value of Optimized Tumor Treating Fields Delivery in Newly Diagnosed Glioblastoma: An Exploratory Cost-Utility Analysis | Jorge Fernando Nino de Rivera | |
| 537-EE | Cost Impact of Tafasitamab combined with lenalidomide and rituximab in relapsed or refractory follicular lymphoma: a Time to next treatment and number needed to treat based pharmacoeconomic analysis. | Bruno A Marques | |
| 539-EE | Healthcare Resource Utilization and Real-World Disease Burden Among Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer in the First-Line Setting | Alison McGeehan | |
| 540-EE | Healthcare System Sustainability in Ecuador: A Cost-Minimization Analysis of Fixed-Dose Subcutaneous Pertuzumab and Trastuzumab Versus Intravenous Administration in HER2-Positive Breast Cancer | Paula Luque | |
| 549-EE | Healthcare Resource Utilization and Real-World Burden of Illness in Patients With PD-L1-Negative Metastatic Triple-Negative Breast Cancer in the First-Line Setting | Alison McGeehan | |
| 551-EE | Impact of the bereavement factor method on caregiver spillover on cost-utility models. | Sarah Pytlak | |
| 552-EE | Dominating RSV: Cost-Effectiveness of Clesrovimab in Infants Born to Unvaccinated Mothers in Argentina | Lucas Perelli | |
| 555-EE | Economic Evaluation of a Fixed-Dose Intranasal Ketamine and Sufentanil Combination for Pediatric Acute Pain in Sweden | Mark Connolly | |
| 556-EE | Budget Impact of Rapid Whole-Genome Sequencing for Critically Ill Pediatric Patients with Rare Undiagnosed Genetic Diseases in the United Arab Emirates | Nordin Charafi | |
| 560-EE | Productivity Loss in Patients with Moderate-to-Severe Thyroid Eye Disease in Spain and Italy: Results from a Real-World Cross-Sectional Study | Moushmi Singh | |
| 561-EE | Economic Impact of Early Diagnosis and Immunoglobulin Treatment for Inborn Errors of Immunity with Focus on Common Variable Immunodeficiency (CVID) in Brazil: A Cost-Effectiveness Perspective | Antoaneta Rashkova | |
| 562-EE | Trajectories and Composition of Costs Across Disease Progression Stages in Duchenne Muscular Dystrophy: A Systematic Review | Silene Giusti | |
| 565-EE | Informing Value-Based Procurement Decisions Through Social Return On Investment: The case of Immunoglobulin Therapy in Primary Immunodeficiencies | Antoaneta Rashkova | |
| 578-EE | Value of Therapeutic Durability in Vision Health: Simulating Clinical Capacity with Faricimab for DME and nAMD in IMSS (Instituto Mexicano del Seguro Social) | Adriana Ureña | |
| 582-EE | Modeling Therapeutic Persistence in Ocular Therapies: A Review of HTA Submissions | Anand Jacob | |
| 586-EE | Relapse and associated healthcare burden in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA): A retrospective cohort study in Germany | Colleen Dumont | |
| 587-EE | Clinical, Economic and Humanistic Burden of Chronic Spontaneous Urticaria in the Gulf Region | Sherif Mohsen | |
| 591-EE | Economic Evidence for Tacrolimus in Kidney Transplant Recipients: A Targeted Literature Review to Support UK Cost-Effectiveness Modelling | Matthew Lyall | |
| 602-EE | Cost-Effectiveness of the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in At-Risk Adults Aged >=60 years in Peru | Gabriela Mendoza | |
| 605-EE | Decision-Context Metadata Improves AI-Guided Economic Model-Structure Triage: A 15-Case Non-Oncology HTA Validation | Leah Moore | |
| 613-EE | Novel Two-Stage Method for Automating the Development of Excel-Based Health Economic Models Using Generative AI | Marcus Read | |
| 614-EE | Societal burden of ischaemic stroke: A nationwide cohort study in Sweden | Michael Hurst | |
| 617-EE | The potential burden of ATTR-CM in Portugal: a global and per functional class cost-of-illness analysis | Débora Figueira | |
| 620-EE | Budget Impact of Adding Acoramidis to Formulary for the Treatment of Transthyretin Amyloid Cardiomyopathy: a United States Health Plan Analysis | Dario Rodriguez | |
| 629-EE | Natural History Modeling of All-Cause Decompensated Cirrhosis: Long-Term Clinical and Economic Burden and Considerations for Future Economic Evaluations | Caitlyn Matuska | |
| 632-EE | Healthcare resource utilization and incidence of obesity-related complications across BMI classes: a multi-country federated study (COST-O) | Lieven Annemans | |
| 633-EE | Therapeutic Inertia and HbA1c Among Adults With Type 2 Diabetes | Maureen Lage | |
| 634-EE | Cost-Effectiveness of Transcutaneous Carbon Dioxide Therapy Versus Standard of Care for Diabetic Foot Ulcer Healing and Amputation Prevention: A Model-Based Analysis From the Swiss Payer Perspective | Natalija P.Petkovic | |
| 636-EE | Projected Impact of Semaglutide on Healthcare Resource Utilisation in the United Kingdom | Robert King | |
| 637-EE | Healthcare Expenditures Associated with Body Mass Index in Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease | Taiwo Adesoba | |
| 639-EE | Progression of Metabolic Dysfunction-Associated Steatohepatitis and Economic Burden: Use of Real-World Health Record Data in England to Inform Economic Models | Yestle Kim | |
| 640-EE | Economic Impact of CDST Use in Crohn´s Disease: A French Budget Impact Model | Cinira LEFEVRE | |
| 641-EE | Clinical and Economic Impact of an Optimized Mesalazine-Based Management Strategy Versus Current Standard Care in Patients with Mild-to-Moderate Left-Sided Ulcerative Colitis in the Netherlands: A Cost-Offset Analysis | Agnella Matic | |
| 643-EE | Economic values of policy interventions to reduce antimicrobial resistance use: a scoping review of model-based economic evaluation studies | Alyssa Grant | |
| 644-EE | Cost-Effectiveness Analysis of Rapid Multiplex PCR Panel for Sepsis Diagnosis in ICU Patients: Vertically Private Plan in Brazil | Gabriel Ogata | |
| 654-EE | Economic Modelling Quality and HTA Outcomes: Population-Coverage Outcomes and Appraisal Timelines Across NICE, CDA-AMC, and PBAC (2020-2025) | Mackenzie Mills | |
| 655-EE | Value of Care Across ICU Survivors Up to Five Years After ICU Admission | Julian van Gemert | |
| 663-EE | Health Economic Impact of Software-Assisted Brain MRI on Treatment Decisions and Outcomes in Relapsing-Remitting Multiple Sclerosis: A Microsimulation Study | Trisha Whitney | |
| 665-EE | Budget-Impact Analysis of Tividenofusp Alfa; a Blood-Brain Barrier-Crossing Enzyme Replacement Therapy for the Treatment of Mucopolysaccharidosis Type II in Pediatric Patients with Neurologic Symptoms | Camille Baker-Smith | |
| 673-EE | Growth in Advanced-Stage Cancer Treatment Costs in England Reflecting Rising Cancer Prescribing Expenditures | Ali Tafazzoli | |
| 674-EE | Economic burden in patients with myelofibrosis: A systematic literature review | Andrii Danyliv | |
| 680-EE | A gateway to future innovations: Real Option Value (ROV) of first-line CDK4/6 Inhibitors in HR+/HER2-negative Metastatic Breast Cancer | Kristen Migliaccio-Walle | |
| 686-EE | Momelotinib results in cost savings vs ruxolitinib for patients with myelofibrosis and moderate to severe anaemia | Jacob Gehrman | |
| 687-EE | Cost-Effectiveness of Axicabtagene Ciloleucel Versus Tisagenlecleucel for Third-Line Treatment of Relapsed or Refractory Large B-Cell Lymphoma: Analysis from the Perspective of the Brazilian Supplementary Healthcare System | Jessika Cristina Bridi | |
| 689-EE | Cost-Effectiveness of Pafolacianine-guided Intraoperative Molecular Imaging with Standard of Care Versus Standard of Care Alone for the Identification of Occult Synchronous Lesions During Lung Cancer Surgical Resections in US | Keith Needham | |
| 691-EE | Informing Future Funding Decisions: A Real-World Cost-effectiveness Analysis of Chimeric Antigen Receptor T-cell Therapy for Relapsed/Refractory Large B-cell Lymphoma | Lisa Masucci | |
| 705-EE | Systematic Literature Review of Cost-Effectiveness, Health-State Utility Values, and Healthcare Costs and Resource Use Evidence Associated with Small Cell Lung Cancer | Tijana Stanic | |
| 707-EE | Economic and Humanistic Burden of Distant Metastasis in Resected High-Risk (Stage IIB-IV) Melanoma: A Systematic Literature Review | Yuexin Tang | |
| 715-EE | Reimbursement and Capacity Implications of Transitioning Patients to Home-Based SCIg in SID and CIDP: A Practice-Level Economic Model in Germany | Antoaneta Rashkova | |
| 716-EE | Economic Impact of Recombinant Activated Factor VII Prophylaxis in Severe Glanzmann Thrombasthenia: A Prospective Cohort Analysis from Saudi Arabia | George Morgan | |
| 723-EE | Economic Burden of Progressive Supranuclear Palsy: A Targeted Literature Review | Taruni Donkana | |
| 724-EE | Cost and HCRU consequences of switching from existing long-term prophylaxis to donidalorsen in hereditary angioedema | Willam Drinkwater | |
| 728-EE | Budget Impact Analysis of Single-Inhaler Triple Therapy (SITT) of Budesonide / Glycopyrronium / Formoterol Fumarate Dihydrate for Moderate to Very Severe Patients With COPD in Argentina | Marina Fiorella Tabares | |
| 734-EE | Review of NICE Submissions and Comparison of Economic Model Structures and Methodological Precedent in Retinal Diseases | Hannah Baker | |
| 738-EE | Economic Burden of Psoriasis with Concurrent or Subsequent Psoriatic Arthritis: A Retrospective Observational Study in Germany | Shun-Chiao Chang | |
| 744-EE | Budget Impact of GIRFT-Aligned Versus Wales-Informed Home Dialysis Targets in the UK: A Scenario Analysis from the NHS Perspective | Araadhna Sinha | |
| 745-EE | Economic Burden of Fluid Overload in Maintenance Hemodialysis Patients in France, Germany, and Italy | Sophie Boeger | |
| 760-EE | Valuing Hidden Inputs to Hospital Care: Willingness to Pay and Willingness to Accept Compensation for Informal Inpatient Caregiving in China | Huixuan Gao | |
8-11 November Vienna

Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|
|